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Abstract 
The use of immunotherapeutic approaches for the treatment of cancer is limited be-
cause of the intrinsic resistance of tumors to T cell infiltration and effector function. 
Enhanced infiltration of T cells can be achieved by inducing an activated tumor mi-
croenvironment utilizing whole body irradiation in mice. However, radiotherapy of 
human cancer with high doses is not applicable in some patients due to complica-
tions associated with organ damage. We hypothesized that locally applied low dose 
irradiation is sufficient to create a niche favoring immune effector cell entry to the tu-
mor.  
The RIP1-Tag5 (RT5) transgenic mouse model expressing the simian virus 40 de-
rived T antigen (Tag) as a model tumor antigen was employed for this study. Follow-
ing in vitro activation, Tag specific T cells derived from donor mice were injected into 
RT5 mice previously irradiated with doses ranging from 0.5 to 6 Gray. Histological 
examination demonstrated that transfer of activated tumor-specific CD4 or CD8 posi-
tive T cells alone resulted in low T cell frequencies in the tumor tissue, whereas a 
combination treatment including locally applied low dose irradiation and adoptive 
transfer of Tag specific T cells boosted tumor infiltration. Reduced tumor hemorrhag-
ing was associated only with the latter treatment and indicated a treatment response. 
Local enrichment of adoptively transferred activated tumor-specific T cells was found 
to modulate the tumor microenvironment providing endogenous T cell subsets ac-
cess to the tumor tissue. The observed effects correlated with the presence of innate 
immune cells in the tumor micromilieu which mediated tumor infiltration of T cells by 
production of nitric oxide (NO). Depletion of this cell population or suppression of NO 
synthase prevented the treatment effect as indicated by tumor regrowth and increase 
in mortality.  
This is the first demonstration of enhanced influx of immune effector cells triggered 
by a combination treatment with local low dose irradiation and adoptive T cell transfer 
that relies on activation of the tumor microenvironment mediated by NO producing 
innate immune cells. We believe this treatment approach can be a foundation for the 
development of a novel and promising cancer therapy that utilizes an activated tumor 
microenvironment to selectively enrich immune effector cells facilitating immune-
mediated tumor destruction. 
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Zusammenfassung 
Das Anwendungsspektrum immunotherapeutischer Maßnahmen für die Behandlung von 
Krebserkrankungen ist, aufgrund der intrinsischen Resistenz von Tumoren gegenüber der 
Infiltrierung durch T-Zellen und deren Effektorfunktionen begrenzt. In Mäusen kann eine 
Steigerung der Infiltration durch T-Zellen durch das Induzieren einer aktivierten Tumor-
Mikroumgebung durch Ganzkörperbestrahlung erreicht werden. Jedoch ist der Einsatz ei-
ner Hochdosis-Strahlentherapie für Krebserkrankungen beim Menschen für manche Pati-
enten nicht geeignet, da Komplikationen aufgrund von Organschäden auftreten können. 
Wir vermuten daher, dass eine lokal applizierte Niedrigdosis-Bestrahlung genügt, um eine 
Nische zu schaffen, die den Eintritt von Immuneffektorzellen in den Tumor begünstigt. 
Das transgene RIP1-Tag5 (RT5) Mausmodell, in welchem Mäuse das vom Simian-Virus 40 
stammende „T Antigen“ (Tag) als Modell-Tumorantigen exprimieren, wurde für diese Studie 
verwendet. Im Anschluss an in vitro-Aktivierung wurden Tag-spezifische T-Zellen in RT5-
Mäuse injiziert, die mit Dosen von 0,5 bis 6 Gray bestrahlt worden sind. Anhand histologi-
scher Auswertung konnte gezeigt werden, dass der Transfer von aktivierten Tumor-
spezifischen CD4 oder CD8 positiven T-Zellen zu niedrigen T-Zell-Frequenzen im Tumor-
gewebe führte, während eine Kombinationsbehandlung aus lokal applizierter Niedrigdosis-
Bestrahlung und adoptivem T-Zell-Transfer die Tumorinfiltration wesentlich verstärkte. Eine 
Reduktion von Tumor-Hämorrhagien war nur mit letzterer Behandlung assoziiert und indi-
zierte ein Ansprechen der Therapie. Des Weiteren wurde gezeigt, dass die lokale Anreiche-
rung adoptiv transferierter, aktivierter Tumor-spezifischer T-Zellen die Tumor-
Mikroumgebung veränderte, wodurch endogenen T-Zell-Subpopulationen Eintritt in das 
Tumorgewebe ermöglicht wurde. Die beobachteten Effekte korrelierten mit der Präsenz 
von Zellen der angeborenen Immunität im Tumor-Mikromilieu, welche die Tumor-Infiltration 
durch T-Zellen mit der Produktion von Stickoxid (NO) vermittelten. Depletion dieser Zellpo-
pulation bzw. Suppression von NO-Synthase verhinderte ein Ansprechen der Therapie, wie 
durch erneutes Tumorwachstum und Anstieg der Mortalität gezeigt werden konnte. 
Diese Studie zeigt zum ersten Mal, dass ein erhöhter Influx von Immuneffektorzellen, der 
durch eine Kombinationsbehandlung aus lokal applizierter Niedrigdosis-Bestrahlung und 
adoptivem Transfer von T-Zellen hervorgerufen wurde, auf einer Aktivierung der Tumor-
Mikroumgebung beruht, welche durch NO-produzierende Zellen der angeborenen Immuni-
tät vermittelt wird. Wir sind der Ansicht, dass dieser Behandlungsansatz eine Basis für die 
Entwicklung einer neuen und vielversprechenden Krebstherapie sein kann, welche eine 
aktivierte Tumor-Mikroumgebung nutzt, um durch selektive Anreicherung von Immun-
effektorzellen eine Tumordestruktion einzuleiten. 
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Ne dubita, cum magna petes, impendere parva. 
[M. Porcius Cato major, Distichs]  
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Abbreviation index 
°C Degree Celsius 
aa Amino acids  
A Alanin  
Ab Antibody  
ADI Adoptive Immunotherapy  
Ag Antigen  
ALCAM   Activated leukocyte cell adhesion molecule 
APC Antigen presenting cell 
B Belgium  
BM Bone marrow 
BSA Bovine serum albumin  
CAM Cell adhesion molecule 
CD Cluster of differentiation  
CLIP Clodronate loaded liposomes 
CpG Cytosine-phosphorothioate-guanine  
CTL Cytotoxic T lymphocyte 
CTLA-4 Cytotoxic T-lymphocyte antigen 4  
D Germany  
d Day  
DC Dendritic cell(s)  
ddH2O Double distilled water  
DKFZ Deutsches Krebsforschungszentrum (German Cancer 
Research Center)  
DMSO Dimethylsulfoxid  
DNA Deoxyribonucleic acid 
EDTA Ethylenediaminetetraacetic acid 
EGFR Epidermal growth factor receptor  
et al. Et alii 
FACS Fluorescence-activated cell sorter (flow cytometry)  
FCS Fetal calf serum  
Fc Fragment crystallisable  
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FGF Fibroblast growth factor  
FITC Fluorescein isothiocyanate  
FoxP3 Forkhead box protein 3  
FSC Forward scatter 
g Gram(s)  
g 9,81m/s 
G Glycin  
GM-CSF Granulocyte and monocyte colony stimulating factor 
GVHD Graft versus host desease 
Gy Gray 
H Histidin  
hr Hour(s)  
HA Hemagglutinin  
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
HLA Human leukocyte antigen  
HPMEC Human primary microvascular endothelial cells 
HUVEC Human umbilical vein endothelial cells 
I Isoleucin  
ICAM intercellular adhesion molecule 
IFN Interferon  
IgG Immunoglobulin G 
IL Interleukin  
int Intermediate  
IU International units  
K Lysin  
l Liter(s)  
L Leucin  
L Ligand  
LD Low-dose 
LPS Lipopolysaccharid  
m Months 
M Molar (mol/l)  
mAb Monoclonal antibody(ies)  
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MACS Magnetic-activated cell sorting 
MAdCAM Mucosal vascular addressin cell adhesion molecule 
ME Mercaptoethanol 
MHC Major histocompatibility complex  
min Minute(s)  
ml Mililiter  
µl Microliter  
N Asparagin  
NaCl Sodium chloride  
NF Nuclear factor 
NK Natural killer  
NL The Netherlands  
NOD/Scid Non-obese diabetic/severe combined immunodeficiency  
n.s. Not significant  
n.t. Not tested  
ODN Oligodeoxynucleotide(s) 
o/n Over night  
PBS Phosphate-buffered saline  
PE Phycoerythrin  
PGE2 Prostaglandin E2  
PLIP PBS loaded liposomes 
PI Propidium iodide  
Q Glutamin  
R Arginin  
rb Retinoblastoma 
RIP Rat insulin promoter 
rpm Rounds per minute  
RPMI Roosvelt Park Memorial Institute  
RT Room temperature  
RT Radiotherapy 
RT5 RIP1-Tag5 
S Serin  
SD Standard deviation  
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SEM Standard error of the mean  
SSC Side scatter  
SV40 Simian virus 40 
T Threonin  
TA Tumor antigen  
Tag T antigen 
TAA Tumor-associated antigen  
TC T cell(s)  
TCR T cell receptor  
TCRtg TCR transgenic 
TGF Transforming growth factor  
Th Helper T cell  
TIL Tumor infiltrating lymphocyte(s) 
TM Trademark  
TNF Tumor necrosis factor  
Treg Regulatory T cell(s)  
trp Transformation related protein 
U Units  
USA United States of America 
V Valin  
VCAM Vascular cell adhesion molecule 
VEGF Vascular endothelial growth factor  
vs. Versus  
v/v Volume per volume  
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w/v Weight per volume  
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1 Introduction 
Until the end of last century it was questioned whether the human immune system 
was capable of recognizing spontaneously arising tumors and whether immune ther-
apy has the potential to become a meaningful treatment for human malignancies. 
Today, cytokines and antibodies are components of widely used cancer treatment 
regimens but also the cellular components of the immune system are being explored 
for their use in immunotherapy. Since T cells play a central role in cell-mediated im-
munity, therapy of human malignancies using T cells is being investigated in many 
disease settings. With recent progress in the understanding of the requirements for 
immune cell activation and their accumulation at tumor sites effective attacks against 
tumors engaging multiple components of the immune system are now possible.  
Despite the efficiency of the immune system to recognize and eliminate transformed 
cells, cancers can develop due to mechanisms evolved by tumors to escape from 
surveillance of immune cells. Recent development in the understanding of the cellular 
and molecular mechanisms that regulate immune responses in the tumor microenvi-
ronment has opened new potential for cancer immunotherapy. However, for the 
translation of this knowledge into effective tumor immunotherapy the problem of tu-
mors escape mechanisms has to be addressed. 
Tumors escape mechanisms are multiple and several of them have been discovered 
over the last decades. Tumor antigens may not be specific enough for discrimination 
from normal host cells. Tolerance may be induced by insufficient costimulation of ac-
cessory molecules on lymphocytes. Tumors may downregulate molecules on antigen 
presenting cells to escape from T cell recognition or produce immune inhibitory mole-
cules such as cytokines or messenger molecules. Furthermore, tumors can also em-
ploy a mechanism to escape from immune-mediated rejection which is based on 
modulation of the tumor vasculature leading to restriction of access of activated effec-
tor T cells to the tumor site. 
Therefore, an effective cellular immunotherapy strategy should not only facilitate im-
mune cell activation but also has to normalize tumor vasculature to allow for accumu-
lation of immune effector cells at tumor sites. 
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1.1 Cellular Immunotherapy 
T cells are able to recognize either unique tumor antigens, which can evolve by 
mutagenesis or viral oncogenesis, or self antigens which are overexpressed or are 
usually restricted to an exclusive developmental phase or tissue (Kawakami et al., 
1994; Mandelboim et al., 1994). T cells recognize these antigens by using clonally 
distributed antigen receptors (T cell receptors, TCRs) that bind to the respective anti-
gen in the context of major histocompatibility complex (MHC) proteins. For activation 
of the tumor directed effector functions, T cells have to be activated by bone marrow–
derived antigen presenting cells (APCs) that present tumor-derived antigens and 
provide essential costimulatory signals (Huang et al., 1994). Sufficiently activated T 
cells recirculate through the blood stream, migrate through endothelium which ex-
presses receptors and chemokines that match their homing pattern and gain access 
to the tumor microenvironment where they need to overcome inhibiting mechanisms 
elicited by the tumor. T cell derived cytokines such as interferon-gamma (IFN-γ) and 
tumor necrosis factor-alpha (TNF-α) can arrest proliferation of tumor cells and inhibit 
neoangiogenesis which is needed for tumor growth. Finally, T cells are able to lyse 
tumor cells by inducing apoptosis via perforin/ granzyme B cytolysis and/or by engag-
ing specialized death receptors (Suda et al., 1995; Trapani and Smyth, 2002). Con-
sequently, for the use of T cells for immunotherapy, a tumor antigen has to be identi-
fied, the antigen has to be provided in an immunogenic format to induce strong 
tumor-specific responses and the frequencies of reactive T cells have to be en-
hanced. However, generating high frequencies of activated tumor reactive T cells 
alone either by stimulation of host T cells or by adoptive therapy has been shown to 
have limited success in immunotherapy, mainly because many tumors can escape 
from surveillance of immune cells. The following paragraphs describe recently devel-
oped vaccination and adoptive cell transfer approaches and improvements to existing 
protocols which have shown potential for the treatment of human tumors. 
 
1.1.1 Stimulation of tumor-specific immune responses in vivo 
Tumor antigens are usually poorly immunogenic because they are naturally pre-
sented in a repressive environment and they are mostly non-mutated proteins aber-
rantly expressed by the tumor which results in induction of tolerance (Sakaguchi et 
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al., 2001). For the generation of therapeutic vaccines activated APCs can be intro-
duced into the patient to compensate for repressive factors from the tumor environ-
ment. This has been achieved by injection of cells such as by ex vivo antigen pulsed 
patient derived APCs or by transplantation of dead tumor cells which are modified to 
secrete factors that elicit local accumulation of APCs (Dranoff et al., 1993). Addition-
ally, injecting activators of APC such as toll-like receptor (TLR) ligands or monoclonal 
antibodies specific to the costimulatory molecule CD40 on APCs with the antigen, or 
by injecting vectors that lead to expression of the antigen and a stimulus to the innate 
immune system have shown some success (Pardoll, 2002).  
Rejection of established tumor masses has been demonstrated in murine studies 
with above mentioned approaches and clinical trials show tumor regressions for 
some patients (Karanikas et al., 2003; Nestle et al., 1998; Rosenberg et al., 1998). 
But in most vaccinated patients only weak or undetectable T cell responses to the 
tumor antigen were found and no clinical benefit could be demonstrated. However, 
during encounter with a replicating foreign pathogen, APC activation and antigen 
presentation have been shown to prolong much longer (reviewed in Baxter and 
Hodgkin, 2002). Therefore, maintaining APC activation and sustaining antigen pres-
entation in vivo will likely be required for vaccines to counteract tumor escape 
mechanisms and to become more efficient. 
Attenuation of negative checkpoint signals that limit T cell responses is another way 
to improve vaccines. Cytotoxic T lymphocyte antigen–4 (CTLA-4) is a cell surface 
molecule and binding to its ligand transmits inhibitory signals to T cells. Blocking of 
this negative regulator of T cell activation by administration of antibodies to CTLA-4 
has shown marked effects in murine models (Tivol et al., 1995). In clinical trials, lym-
phocytic infiltration into tumors and significant tumor-specific immune responses were 
demonstrated, resulting in complete regressions of advanced disease in some pa-
tients (Phan et al., 2003; van Elsas et al., 2001). This example of effectively disrupt-
ing inhibitory signals demonstrates that further breaking tumor immune resistance 
may yield substantial therapeutic benefit. 
Inhibitory signals to tumor-specific immune responses can be transmitted specifically 
by a specialized subset of T cells. T regulatory (Treg) cells are a subset of T cells ca-
pable to suppress T cell responses and were detected in settings of persistent anti-
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gen stimulation in the absence of inflammatory signals, particularly in the presence of 
transforming growth factor beta (TGF-ß). Since these cells have been found to ac-
cumulate in some cancer patients (Woo et al., 2002), depletion of these cells in vivo 
can support the potential of T cell responses. Murine studies show potential for tumor 
therapy (Sutmuller et al., 2001), but as with abrogation of CTLA-4 signaling, systemic 
ablation of Treg cells increases autoimmunity. Therefore, for enhancing existing tu-
mor immunotherapy protocols not only counteracting tumor escape mechanisms 
have to be attributed, but also local enhancement of immune effector cell accumula-
tion and function is critical. 
 
1.1.2 Adoptive transfer of T cells for tumor immunotherapy 
Infusions of lymphocytes from a matched donor have been used with success for the 
treatment of leukemia. But the use of these allogeneic cell infusions for tumor immu-
notherapy is often associated with severe and life-threatening graft-versus-host dis-
ease (GVHD) syndromes (Childs et al., 2000). A better alternative has been to rein-
fuse in vitro expanded autologous tumor-reactive T cells back into tumor patients. 
Tumor-infiltrating lymphocytes can be used as an enriched source of tumor-reactive 
cells, but since these cells recirculate trough the body they can also be obtained from 
peripheral blood. Using this approach, tumor-reactive T cells have been expanded to 
large numbers in vitro and could be reinfused to get augmented in vivo frequencies 
(Dudley and Rosenberg, 2003). These therapies mediated regression and occasion-
ally complete elimination of large disseminated tumor masses without occurrence of 
life-threatening toxicities, but only a fraction of patients responded. Again, this obser-
vation points to the requirement that the transferred cells not only have to be acti-
vated but also must persist to counteract tumor escape mechanisms and mediate an 
effective response.  
It has been shown that lympho-depletion of patients before adoptive transfer of T 
cells can promote proliferation of transferred T cells, allowing to create an in vivo 
repertoire dominated by the effector population (Dudley et al., 2002). This treatment 
is probably taking advantage of endogenous homeostatic mechanisms that restore 
lymphocyte numbers after lymphopenia and eliminate host Treg cells. This exempli-
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fies that tumor induced tolerance can be reverted and thereby large quantities of tu-
mor reactive immune effector cells generated. 
To improve adoptive therapy, T cell clones instead of polyclonal T cell lines can be 
used, because the specificity, avidity, and effector functions of infused cells can be 
improved. The transfer of antigen-specific CD8 positive T cell clones has been shown 
to be effective for prevention of viral infections and treatment of malignant disease 
(Walter et al., 1995; Yee et al., 2002). Infusion of genetically modified T cells with en-
hanced tumor recognition was shown to be feasible using integrating vectors. High-
affinity chimeric transmembrane receptors with the external recognition structure of 
an antibody that allows MHC-independent antigen binding but uses a signaling do-
main of a T cell receptor have been used to improve T cell recognition of tumors in a 
murine study (Brentjens et al., 2003). However, recognition of tumor antigens by cy-
totoxic T cells is essential but not sufficient for effective cancer immunotherapy. So 
far, it has yet to be shown that T cell clones retain a functional phenotype, including in 
vivo cytolytic activity and the ability to travel to tumor sites without prematurely suc-
cumbing to apoptosis in the treatment of established human tumors which evolved a 
plethora of immune escape mechanisms. 
The possibility to design T cells capable of circumventing many of the obstacles es-
tablished by tumors could result in sufficiently activated T cells that can gain access 
to the tumor site. However, most studies failed at addressing the complexity of the 
tumor microenvironment which holds stroma cells and the tumor endothelium which 
represents a crucial impediment for T cell extravasation. The following section out-
lines the role of tumor vasculature in controlling lymphocyte influx to the tumor site as 
a central mechanism in tumor immune resistance. 
 
1.2 Tumors escape from immunological effector mechanisms 
1.2.1  Tumor resistance mediated by the tumor vasculature 
The efficacy of tumor-specific cellular strategies decreases with tumor size, demon-
strating that tumors possess mechanisms to escape immune destruction. A loss of 
antigen expression by the tumor and abnormal expression of growth factors were 
shown to down-regulate immune effector function (Pardoll, 2003). Furthermore, infil-
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trating leukocytes are found in the tumor stroma and can contribute to tumor immune 
escape. The tumor stroma is a network of extracellular matrix that harbors inflamma-
tory cells, such as macrophages, granulocytes and dendritic cells (DCs) (Dvorak, 
1986) which are known to produce factors that promote tumorigenesis and may also 
contribute to immune evasion, for instance, by preventing DC maturation (Mantovani 
et al., 2002). 
Adoptive transfer of ex-vivo-expanded, tumor-specific T cells was thought to be a so-
lution to overcome poor activation of intrinsic effector cells, failure of vaccination or 
tumor resistance mechanisms (Dudley and Rosenberg, 2003), since tumor-reactive T 
cells are capable of migrating to and destroying the tumor tissue. But it has been 
shown that even fully activated tumor-specific T cells can fail to reject established, 
immunogenic tumors (Ganss and Hanahan, 1998; Ganss et al., 2002; Garbi et al., 
2004) These studies demonstrated that the tumor endothelium as part of the micro-
environment represents an impediment for T cell extravasation. Moreover, endothelial 
cells in the tumor microenvironment can support carcinogenesis by forming new 
blood vessels in the process of angiogenesis (Hanahan and Folkman, 1996). 
Blood vessels are not only essential for nutrient delivery to the tumor but tightly con-
trol leukocyte extravasation and therefore require orchestration of multiple receptor-
ligand interactions as well a favorable cytokine/chemokine micromilieu (Butcher, 
1991). Moreover, ongoing angiogenesis induces profound morphological and mo-
lecular changes in tumor blood vessels (Ryschich et al., 2002; St Croix et al., 2000) 
and thus contributes to the tumor's intrinsic resistance to infiltration. Therefore, effec-
tive tumor immune strategies require both highly activated effector cells and need to 
modulate the tumor environment to be more permissive for infiltration by immune ef-
fector cells. In particular, normalization of the tortuous tumor blood vessel network is 
essential to enhance immune cell accumulation at the tumor site. 
 
1.2.2 Abnormal Blood Vessel Architecture and Function in Tumors 
Along with the development of the tumor microenvironment a tumor blood vessel net-
work is formed characterized by an impaired angiogenesis regulation and continuous 
formation of neovessels. 
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Blood vessels in tumors have been shown to be dilated, twisted and heterogeneous 
in spatial distribution (Jain, 1988). They originate from normal microvessels which 
consist of arterioles, capillaries and venules, and form a well-organized, regulated 
and functional architecture (Jain, 2003). The structural hallmark of normal vascula-
ture is an organized dichotomous branching, whereas in tumor vasculature unorgan-
ized multiple branches with uneven diameters are found (Chang et al., 2000; di 
Tomaso et al., 2005).  
To allow for rapid exchange of molecules between tumor blood vessels and sur-
rounding tissue large inter-endothelial junctions, increased numbers of sinusoid 
stretches, vesico-vacuolar channels, and a lack of normal basement membrane are 
often found (Winkler et al., 2004). In tumors perivascular cells such as pericytes and 
smooth muscle cells also show an abnormal morphology and have heterogeneous 
associations with tumor vessels. 
The underlying mechanisms behind the formation of tumor blood vessels are not well 
understood, but the imbalance of pro- and anti-angiogenic factors which are released 
by both the tumor cells and the tumor infiltrate are considered to be a key contributor 
(Jain, 2005). The fluid pressure which is produced by proliferating tumor cells gener-
ates mechanical stress on the vessels in tumors, which is also thought to be one con-
tributing factor in the conversion of normal vessels to tumor vessels (Padera et al., 
2004). 
Furthermore, tumor blood flow velocity is not equally distributed among different tu-
mor vessels and can even reverse its direction. Therefore, tumor areas which are 
poorly or not at all perfused are frequently seen. The heterogeneity of tumor blood 
flow is considered to be the main barrier which hinders the delivery and efficacy of 
therapeutic agents to tumors.  
Impaired angiogenesis regulation of tumor vessels is also responsible for reduced 
expression of leukocyte adhesion receptors and unresponsiveness to inflammatory 
stimuli. Consequently, this results in impaired lymphocyte infiltration of tumors. 
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1.2.3 Angiogenesis controls lymphocyte infiltration of tumors 
Angiogenesis is required for the outgrowth and metastasis formation of tumors 
(reviewed in Carmeliet, 2005) and is regulated by stimulators and inhibitors. In nor-
mal resting vasculature angiogenesis is turned off, but tumors can stimulate angio-
genesis through production of cytokines such as vascular endothelial cell growth fac-
tors (VEGFs) and fibroblast growth factors (FGFs) by the tumor cells. It has long 
been shown that tumor blood vessels have a limited capacity to express adhesion 
molecules and that tumor cells are involved in the modulation of the expression lev-
els of adhesion receptors, through the production of angiogenic growth factors 
(Gamble and Vadas, 1988; Wu et al., 1992). Reduced expression of leukocyte adhe-
sion receptors and unresponsiveness to most inflammatory stimuli has been termed 
tumor endothelial cell anergy (Griffioen et al., 1996). This anergy has been demon-
strated to add to the tumors potential to abrogate immune surveillance mechanisms 
and escape from immunity, allowing tumor outgrowth and metastasis formation. 
It was found that endothelial cells isolated from human tumors expressed significantly 
lower levels of adhesion molecules such as intercellular adhesion molecule-1 
(ICAM1), which are involved in interactions between lymphocytes and the vessel wall 
and mediate lymphocyte transmigration (Griffioen et al., 1996; Melder et al., 1996). 
Studies of in vitro adhesion assays revealed that endothelial cells exposed to tumor 
derived growth factors were shown to be unresponsive to inflammatory stimuli 
caused by cytokines such as IL-1 (interleukin-1), IFN-γ, and TNF-α. These cytokines 
are known to induce an adhesive phenotype in mature endothelium by upregulation 
of adhesion molecules. However, endothelial cells driven into angiogenesis by tumor 
derived growth factors were refractory to these signals (Griffioen et al., 1996).   
Multiple studies indicate that the in vitro exposure of endothelial cells to angiogenic 
growth factors reduces the adherence of leukocytes under static conditions (Nooijen 
et al., 1998) and both rolling and firm adhesion under dynamic conditions (Griffioen et 
al., 1998). In vivo studies using a FGF or VEGF delivery system showed that the ex-
posure to these factors reduced adhesive properties of endothelial cells even after 
stimulation with TNF-α (Tromp et al., 2000). Moreover, in several in vivo models of 
highly angiogenic tumors it was shown that leukocyte rolling as well as firm adhesion 
to the vessel wall in the tumor vasculature was markedly reduced (Dirkx et al., 2003).  
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The concept of endothelial cell anergy in tumors clearly reveals the need to include 
treatment options into immunotherapy approaches that specifically normalize tumor 
blood vessels to allow enhanced lymphocyte interaction with the endothelium and 
tumor infiltration. 
 
1.2.4 Breaking tumor-intrinsic resistance mechanisms  
In the RIP1-Tag5 (RT5) mouse model of spontaneous tumors, the capability of tumor 
antigen reactive T cells to infiltrate malignant tissue is lost during tumor progression, 
resulting in tumor outgrowth. Moreover, the model is reflecting in many ways thera-
peutic failures in cancer patients because conventional therapeutic approaches 
known to enhance costimulation and antigen presentation in vivo or to increase the 
frequency of tumor antigen reactive T cells were proved to be unsuccessful (Ganss 
and Hanahan, 1998; Ganss et al., 2002; Garbi et al., 2004). 
Angiogenesis in RT5 mice is the first step to multistage tumorigenesis where the qui-
escent tumor vasculature in early neoplastic lesions undergoes an angiogenic switch 
and gradually converts into a chaotic network of tumor vessels (Hanahan and Folk-
man, 1996). Remarkably, interactions between leukocytes and endothelium which 
are crucial for transmigration and extravasation are lost concomitant with the earliest 
stage of neovascularization, implying that angiogenesis creates a barrier for effector 
cell extravasation (Ryschich et al., 2002).  
It was shown that irradiation as a proinflammatory stimulus in a non-lymphopenic en-
vironment rendered RT5 tumors accessible for massive infiltration by adoptively 
transferred, tumor antigen-specific effector T cells and resulted in complete rejection 
of well-established tumors over a period of weeks (Ganss et al., 2002). During the 
phase of regression the aberrant tumor vasculature was transformed into capillaries 
of normal appearance and correlated with strong induction of IFN-γ and secretion of 
angiostatic molecules by infiltrating macrophages. These findings demonstrate that 
complex interactions of immune and stromal cells can inhibit angiogenesis not by 
induction of endothelial cell death, but by reversing vessel abnormalities resulting in 
improved immunotherapy. 
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The present study employs the RT5 tumor model to demonstrate the use of a combi-
nation therapy which is able to enhance immunotherapy and which can be translated 
into the clinic for the treatment of human tumors. The following section outlines how 
tumor immune resistance is mediated by endothelial anergy in this model and the 
consequences for extravasation of lymphocytes to the tumor site. 
 
1.3 RIP1-Tag5 as a model for autochthonous tumor growth 
1.3.1 Spontaneous tumors arise from multistage carcinogenesis 
events 
In the RT5 model as well as many human tumors the angiogenesis regulation is im-
paired and neovessels are formed continuously (reviewed in Bergers and Benjamin, 
2003). The tumor blood vessels in this model show abnormal vessel architecture and 
function. Therefore, hemorrhages are frequently observed as the high vessel leaki-
ness allows erythrocytes to pass unhindered into the tumor parenchyma; further-
more, normal blood flow in the tumors is impaired (Jain, 2003; Ryschich et al., 2002) 
In RT5 mice the onco-gene SV40-Tag (Simian Virus 40 large T antigen) is expressed 
under the control of the rat insulin promoter (RIP). By binding of the onco-protein to 
the tumor suppressors transformation related protein 53 (trp53) and retinoblastoma 1 
(rb1) these are inactivated causing transformation of SV40 expressing cells (Blouw et 
al., 2003). Expression of SV40-Tag is induced specifically in the beta-cells in the Is-
lets of Langerhans and begins in adult animals at the age of 10 weeks (Hanahan, 
1985). Over a time course of 20 weeks 2 percent of the roughly 400 islets develop to 
highly vascularized, solid tumors (Hanahan and Folkman, 1996). At the age of about 
31 weeks animals die of hypoglycemia, due to high insulin production in the beta cell 
tumors (Ganss and Hanahan, 1998). The tumor development in these animals pro-
ceeds through defined stages: In normal islets the SV40-Tag expressing beta-cells 
show no enhanced proliferation. In the first stage of tumor progression the onco-gene 
expression causes a focal hyperproliferation of the beta-cells in about 50% of all is-
lets, which itself is not sufficient for the development of solid tumors. The next stage 
is defined by growth of new blood vessels (neovascularization) in some of the hyper-
platic islets leading to angiogenic islets at an age of 16 weeks. Finally, encapsulated 
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tumors arise from angiogenic islets, which invade into the exocrine pancreas at a low 
frequency (Ganss and Hanahan, 1998; Ryschich et al., 2002). 
 
1.3.2 Failing immune destruction of non-tolerogenic tumors 
In RT5 mice the SV40-Tag transgene is not expressed during embryonic develop-
ment, it is not recognized as a self-antigen and the animals do not develop tolerance. 
Therefore, pre-neoplastic lesions are infiltrated by SV40-Tag specific lymphocytes 
(Ganss and Hanahan, 1998). Despite the presence of self-reactive T cells, insulitis 
does not lead to the immunological destruction of beta cells. Solid tumors are free of 
infiltrating lymphocytes and escape from tumor-specific immune responses in this 
model. Neither a higher frequency of tumor-specific T cells nor a more efficient T cell 
priming by co-expression of the costimulatory molecule B7.1 and SV40-Tag (Ganss 
and Hanahan, 1998), or adoptively transferred ex vivo activated tumor-specific CD4 
or CD8 positive T cells (Garbi et al., 2004) lead to tumor eradication. 
In RT5 mice functional cytotoxic lymphocytes can be generated throughout the tumor 
development, as it has been shown by immunization studies using SV40 Tag pep-
tides, but a tumor controlling effect of this vaccination was only seen in early stages 
of tumor progression. Therefore, the lack of tumor elimination does not rely on a sys-
temic induction of tolerance (Garbi et al., 2004). A defect in priming of tumor-specific 
lymphocytes as a result of low antigen amounts which can be presented in lymph 
nodes is unlikely, because adoptively transferred naive tumor-specific CD4 or CD8 
positive T cells are shown to be successfully activated in the host (Ganss et al., 2002; 
Garbi et al., 2004) 
Extravasation of lymphocytes into the tumor site is hindered already at the beginning 
of neovascularization in the hyperplastic beta-cell islets (Ryschich et al., 2002), dem-
onstrating the effect of the angiogenic switch on endothelial properties that leads to 
expression of proteins which are typical for angiogenetic vasculature (Griffioen et al., 
1996; St Croix et al., 2000). It is conceivable that angiogenesis is important for the 
tumor progression in RT5 mice taken the evidence that blocking of the angiogenic 
switch in premalignant lesions inhibits the formation of solid tumors (Bergers et al., 
1999; Bergers et al., 2003). 
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During the tumor development a characteristic miromillieu is formed in the RT5 tu-
mor. This is reflected by the morphological anomalies of the blood vessels, impaired 
leukocyte attachment to the endothelium and the appearance of hemorrhages. As a 
consequence lymphocytes are excluded from the tumors. It has been shown that 
lymphocytes can be recruited to the tumor and that the tumor blood vessels can be 
normalized by interference with the micromilieu. Irradiaiton (Ganss et al., 2002) or 
systemic administration of cytosine-phosphorothioate-guanine-containing oligode-
oxynucleotides (CpG-ODN) (Garbi et al., 2004) induced a proinflammatory micromi-
lieu which allowed infiltration of adoptively transferred T cell receptor transgenic 
(TCRtg) effector T cells into the tumor. These were able to eliminate solid tumors af-
ter massive infiltration (Ganss et al., 2002; Garbi et al., 2004). This combined radia-
tion-/immunotherapy triggered a remodeling of the tumor vasculature which was 
reminiscent of that from normal tissue. This process was referred to as vascular nor-
malization (Ganss et al., 2002). Treated tumors did not show lacunae or hemor-
rhages and showed normal vessel diameters. This normalization was ascribed to the 
induction of proinflammatory and angiogenesis-inhibiting factors from innate immune 
cells (Ganss et al., 2002). 
Tumor vessel normalization by induction of a proinflammatory environment using ir-
radiation is employed also in the present study to enhance immunotherapy in RT5 
mice. The following section describes how irradiation especially with regard to appli-
cation of low doses affects both the vasculature and the immune system.  
 
1.4 Radiation therapy of tumors 
1.4.1 Radiosensitivity of vascular tissue 
Treatment of cancer patients with therapeutic ionizing radiation doses which are usu-
ally higher than 10 Gy and are typically used for treatment of most tumor entities at a 
dose of 50 Gy (Okunieff et al., 1995) is significantly compromised by the develop-
ment of damage to normal tissue, which occurs within days after exposure (Bentzen, 
1997; Kiltie et al., 1999). 
The radiation response consists of a first wave of acute effects which occur within 24 
hours and are dominated by apoptotic cell death of endothelial cells (Pena et al., 
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1997). The second wave of late vascular effects occurs within months after irradia-
tion. Frequently observed effects consist of capillary collapse, thickening of the 
basement membrane and capillary dilation (Pena et al., 2000). 
Since capillaries are the most radiosensitive part of the vasculature, injury of capillar-
ies by radiation is the main cause for tissue radiosensitivity (reviewed in Fajardo et 
al., 2001). One of the key characteristics of endothelial radiation response is leuko-
cyte attachment, endothelial cell swelling, and increased capillary permeability 
(Jaenke et al., 1993). As a consequence of irradiation, detachment of endothelial 
cells from the basal lamina, cell death and therefore loss of entire capillary segments 
are often observed, resulting in tissue ischemia or regrowth of lost vessels in some 
organs (reviewed in Fajardo, 1989). Capillaries also show more morphological 
changes than larger vessels after irradiation making a shift in size distribution to lar-
ger diameters (Dimitrievich et al., 1984). 
On a molecular level, within the first wave of irradiation induced changes in endothe-
lial cells, expression of structural proteins can be detected in these cells, which affect 
their physiological appearance (O'Connor and Mayberg, 2000). The hallmarks of this 
process are alterations in the distribution of filamentous actin, cell retraction and a 
dose-dependent increase in trans-endothelial flux of low–molecular-weight solutes 
(Friedman et al., 1986; Waters et al., 1996). Furthermore, irradiation induces altera-
tions in the synthesis and secretion of a variety of growth factors and chemoattrac-
tants and an upregulation of injury markers is frequently detected (Nicolson et al., 
1991). Finally, a fraction of the surviving endothelial cells after irradiation exposure 
form giant cells which are arrested in cell cycle and are permanently unable to prolif-
erate (Rubin et al., 1989). 
Although, tumor treatment using high doses of irradiation is associated with the risk 
of induction of toxicities especially for gastro-intestinal tumors, it is a “gold standard” 
treatment for many malignancies. The success of this treatment does at least in part 
rely on its immunostimulatory effects. 
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1.4.2 Immunostimulatory effects of ionizing radiation  
Current success of radiotherapy relies on the well-established ability to kill cancer 
cells and other cells within the tumor stroma, including endothelial cells and intratu-
moral lymphocytes (Watters, 1999). One explanation is based on a model that pre-
dicts increased tumor antigen release upon irradiation which induces tumor cell killing 
and tumor antigen uptake by DC and presentation to T cells (Larsson et al., 2001). 
The role of radiotherapy for promotion of tumor antigen presentation by DC has been 
explored in preclinical studies. These studies revealed that tumor immunity can be 
elicited in vivo when tumor irradiation is combined with a DC transfer or an admini-
stration of DC growth factors to increase DC numbers in tumor-bearing mice 
(Chakravarty et al., 1999; Demaria et al., 2004). It has yet to be shown that radio-
therapy on its own is able to enhance tumor immunity. 
An optimal activation of T cells by DC presenting tumor-derived antigens can only be 
achieved in the presence of inflammatory or “danger” signals. Danger signals which 
are generated upon radiation exposure are thought to act by stimulating DC to ma-
ture so that they can efficiently present antigens, but their nature remains largely un-
defined (reviewed in Bianchi, 2007; McBride et al., 2004). The cytokines IL-1 and 
TNFα and other inducers of DC maturation can be induced by radiation both in vitro 
and in vivo (Hong et al., 1999; Rieser et al., 1997; Steinauer et al., 2000). Therefore, 
radiotherapy might provide at least some of the necessary maturation signals which 
improve T cell–mediated tumor immunity.  
Another effect of irradiation which may improve tumor immunity might influence the 
effector phase of tumor cell killing. Radiation therapy has been shown to upregulate 
expression of death receptors, such as TNF receptor superfamily member 6 (Fas), 
but also MHC I and costimulatory molecules on tumor cells. This might enhance their 
tendency to either die or be recognized by immune effector cells (Chakraborty et al., 
2003; Garnett et al., 2004; Sheard, 2001). It has been shown that after irradiation 
mouse colon adenocarcinoma tumor cells are sensitized to killing by adoptively trans-
ferred T cells trough irradiation induced upregulation of Fas on the tumor cells which 
can then be cross-linked by Fas-Ligand on T cells (Chakraborty et al., 2004). 
Additionally, it was reported that both APCs and effector T cells show improved hom-
ing to the tumor after irradiation (Ganss et al., 2002; Nikitina and Gabrilovich, 2001). 
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This effect may be elicited by radiation induced inflammatory signals and by changes 
in extracellular matrix proteins and in the expression of adhesion molecules by endo-
thelial cells (Hallahan et al., 2003; Hallahan and Virudachalam, 1999; Ryschich et al., 
2003). One report highlights the distribution of cell adhesion molecules to the vascu-
lar lumen after irradiation of tumor vessels but not normal vessels, an effect which 
might increase the entry of effector T cells into tumors (Tanigawa et al., 2001). 
While the potential for radiotherapy to elicit tumor immunity has been described in 
numerous reports, clinical success has yet to be demonstrated. However, strategies 
tested in preclinical studies have shown promise in enhancing tumor immunity by 
combining radiation with recently developed approaches in the immunotherapy field 
(reviewed in Antonia et al., 2004). Low-dosed (LD) radiotherapy could be an alterna-
tive to enhance immunotherapy for human cancer when treatment with high doses is 
not applicable due to high associated risk of organ toxicity. 
1.4.3 Dichotomy of the irradiation dose response 
The molecular responses following ionizing irradiation and the subsequent radiation-
related events have started to be explored in detail in the past years (Dent et al., 
2003; Hallahan et al., 1995). The upregulation of genes implicated in recognition and 
repair of damaged DNA and in regulation of cell death have been recognized as early 
molecular events. Later events include the induction of inflammation, which is under 
the control of transcription factors such as NF-κB (Hong et al., 1999; Weichselbaum 
et al., 1994). These factors are required for the expression of immune effector mole-
cules such as cytokines, adhesion molecules and enzymes such as inducible nitric 
oxide synthase (iNOS) as well as molecules involved in the induction of cell death or 
DNA repair (Kracht and Saklatvala, 2002; Pahl, 1999). Although the induction of tran-
scription factors and cytokines has been described after high doses of irradiation 
(e.g. 7–50Gy), there are only few reports about their activation by low-dose (LD) irra-
diation, which is usually applied in fractions of up to 2 Gy in a total dose of up to 12 
Gy. 
The relationship between the radiation dose and inflammatory response is however 
dichotomous. Radiation doses as low as 1 Gy are sufficient to exert pro-inflammatory 
effects (Hong et al., 1999), whereas lower doses reveal anti-inflammatory activity im-
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plicating that complex mechanisms seem to differentially operate at different doses 
and times (Joiner et al., 2001). 
 
1.4.4 Effects of LD irradiation on endothelial cells   
Since the adhesion of leukocytes to endothelial cells represents an initial step in the 
transmigration process, several authors analyzed the effect of irradiation on the leu-
kocyte adhesion using dynamic and static experimental conditions ((Hildebrandt et 
al., 2002; Kern et al., 2000; Roedel et al., 2002). In a static adhesion assay, where 
integrin mediated adhesion dominates, radiation doses of 0.3 - 0.6 Gy reduced the 
adhesion of leukocytes to endothelial cells but it was increased with radiation doses 
of 1 - 3 Gy. Higher doses than 3 Gy again reduce the adhesion of leukocytes to endo-
thelial cells. The same was proven in a dynamic adhesion assay, where selectin me-
diated adhesion was enhanced with radiation doses of 1 - 3 Gy compared to lower 
doses (Hildebrandt et al., 2002; Rodel et al., 2004). An attenuated expression of the 
cell adhesion molecule E-selectin was documented with irradiation doses less than 1 
Gy but not with more than 1 Gy (Hildebrandt et al., 2002; Roedel et al., 2002). Addi-
tionally an induction of ICAM1 by irradiation with doses higher than 4 Gy has been 
reported. 
Endothelial cells play a pivotal role in the transmigration process of leukocytes be-
cause they are both able to recruit leukocytes and have the capacity to express cyto-
kines and growth factors. The cytokine profile of stimulated endothelial cells following 
LD irradiation showed an elevated expression of TGF-ß at an irradiation dose of less 
than 1 Gy but was normalized using 2-3 Gy (Roedel et al., 2002). Several lines of 
evidence suggest that TGF-ß directly or indirectly mediates the decreased leukocyte 
adhesion following LD irradiation. For example, treatment using anti-TGF-ß antibody 
restored the adhesion of leukocytes to irradiated endothelial cells. 
There is also considerable evidence for the contribution of the transcription factor NF-
κB in the cellular responses to irradiation as well as in inflammatory processes. In 
activated human endothelial cells, LD irradiation resulted in the induction of NF-κB 
DNA binding and transcriptional activity at doses from 0.25 to 2 Gy (Prasad et al., 
1994). By specific blocking of the transcriptional activity of NF-κB (Miagkov et al., 
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1998), the induction of inflammatory cytokines such as IL-1 and TNFα was abro-
gated. These findings demonstrate that NF-κB governs inflammatory cytokine re-
sponses in endothelial cells which can be enhanced using LD irradiation. 
Whereas irradiation with high doses is established to exert pro-inflammatory effects, 
LD radiotherapy fractions below 1 Gy are clinically well known to exert anti-
inflammatory and analgesic effects on several inflammatory diseases and painful de-
generative disorders. Above mentioned studies show, that irradiation doses of 2 Gy 
or higher have the potential to enhance lymphocyte binding to endothelium and in-
duce proinflammatory responses. This radiation regimen should therefore be most 
effective to enhance cancer immunotherapy in a setting where high dose radiother-
apy can not be used. 
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2 Objectives 
Several studies which employed vaccination or adoptive cell therapy to treat tumors 
have shown that the generation of high frequencies of activated tumor reactive T 
cells alone has limited success in immunotherapy. It has been shown that this mainly 
depended on the ability of tumors to escape from immune destruction engaging sev-
eral mechanisms. Tumors can control of extravasation of immune effector cells at the 
level of tumor endothelium which forms the microvasculature in the tumor microenvi-
ronment. Therefore, tumor microvessels show reduced expression of leukocyte ad-
hesion receptors and unresponsiveness to conventional inflammatory stimuli. Conse-
quently, this results in impaired lymphocyte infiltration of tumors. Modulation of the 
tumor environment has been shown to render it more permissive for infiltration by 
immune effector cells.  
To create a preclinical system that allows evaluation of the combination of immuno-
therapy with irradiation the following objectives were formulated: 
i. Establishment of a protocol for isolation and in vitro cultivation of human pancre-
atic tumor derived microvascular endothelial cells.  
ii. Titration of the minimum effective dose of gamma irradiation needed to induce an 
activated phenotype of endothelial cells in vitro. 
iii. Establishment of a immunotherapeutic treatment in a mouse model of spontane-
ous autochthonous tumor growth using adoptive transfers of CD4 and CD8 posi-
tive TCRtg tumor-specific T cells 
iv. Application of local low dose irradiation of tumors in vivo and characterization of 
the microvasculature and infiltrating T cell subsets with and without adoptive 
transfer of T cells 
v. Defining pathways that can regulate tumor infiltration and respond to irradiation 
treatment and testing their importance in vivo by abrogation of cell populations 
and / or blockage of effector mechanisms 
vi. Employment of studies of tumor growth intervention and survival  
vii. Comparison of adoptive transfers with alternative strategies to elicit tumor infiltra-
tion 
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Materials and Methods 
2.1 Materials 
2.1.1 Chemicals and enzymes 
Product Source of Supply  
β-mercaptoethanol  Sigma, Taufkirchen  
Aceton Sigma, Taufkirchen  
Agarose  GibcoBRL, Karlsruhe  
Biocoll Biochrom, Berlin 
Bovine serum albumin (BSA)  Roche Diagnostics GmbH, Mannheim  
Collagenase Typ1 CLS1      Cell Systems, Heidelberg; D  
Deoxynucleotides (dNTPs) Bioline, Luckenwalde 
Dispase I       Roche, Darmstadt; D 
EDTA (versen) Biochrom, Berlin 
Ethanol  VWR, Darmstadt 
Ethidiumbromid  Roth, Karlsruhe  
Fetal calf serum (FCS)  PAN Biotech, Aidenbach  
Freund’s Adjuvant, Incomplete Sigma, Taufkirchen 
Glycerol gelatine, Kaiser's Merck KGaA, Darmstadt 
KETANEST S 25 mg/ml Pfizer Pharma GmbH, Berlin 
Marker 1kb DNA-ladder  GibcoBRL, Karlsruhe  
Phosphate buffered salt solution (DPBS), 
Dulbecco’s 
Sigma, Taufkirchen 
Proteinase K  Roche Diagnostics GmbH, Mannheim  
RPMI-1640 Sigma, Taufkirchen  
Rompun 2% Bayer HealthCare, Leverkusen 
Taq-DNA-Polymerase  Bioline, Luckenwalde 
Tris-Acetat-EDTA (TAE )  GibcoBRL, Karlsruhe  
Trizol Invitrogen, Darmstadt 
Tween20  Sigma, Taufkirchen  
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2.1.2 Laboratory supplies  
Product Source of supply  
Cell strainer  NUNC, Wiesbaden  
Cryomold tissue molds  Sakura Finetek Germany GmbH, Staufen 
Cryotubes (1.8 ml)   Corning B.V., Schipol-Rijk, Netherlands  
Cover Slips (24 x 50 mm)   R. Langenbrinck, Teningen, Germany  
Combitips   Eppendorf, Hamburg, Germany  
Cell Culture Test Plates    TPP, Trasadingen, Switzerland  
DAKO Pen  DAKO Diagnostika, Hamburg  
Disposable syringes (1-50 ml)   BD Pharmingen, Heidelberg, Germany  
Disposable scalpels   PfM AG, Köln, Germany  
Disposable pipettes   Renner, Darmstadt, Germany  
FACS-tubes   Greiner, Frickenhausen, Germany    
MACS columns  Miltenyi, Bergisch-Gladbach  
Parafilm American National Can Company, USA  
Petri Dishes (tissue culture-treated)   Biochrom, Berlin, Germany  
Pipette tips (2, 20, 100, 200, 1000 µl)   Gilson, Bad Camberg, Germany  
Plastics  Corning B.V. Life Sciences, Amsterdam, 
The Netherlands 
Safe-Lock Reaction tubes (0.5 ml, 1 ml)   Eppendorf, Hamburg, Germany  
Sterile-filter (0.22 µm)   Millipore, Molskeim, France    
Tissue-Tek® O.C.T™ Compound Sakura Finetek Germany GmbH, Staufen 
TPP tissue culture flasks (T75)   Sigma Aldrich, Deisenhofen, Germany 
Tubes (15 ml, 50 ml) Biochrom, Berlin, Germany  
 
2.1.3 Media and buffers  
Product  Composition   
FACS staining buffer  1x  PBS 
 0.5% (w/v)  BSA 
 0.01% (w/v)  NaN3 
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Product  Composition   
ACK lysis buffer 0.15 mM  NH4Cl 
 10 mM  KHCO3 
 0.1 mM  Na2EDTA 
  pH 7.3 
Tail buffer  100 mM  Tris-HCl, pH 8.5 
 5 mM  EDTA 
 0.2% (w/w)  SDS 
 200 mM  NaCl 
TE buffer  10 mM  Tris 
 1 mM  EDTA 
  pH 8.0 
ECBM ECBM MV      10 ml  
 HEPES    10 mM 
 Penicillin    50 µg/ml 
 Gentamycin 50 µg/ml 
 bFGF      560 U/ml  
 Hydrocortisone   100 U/ml 
  pH 7.4 
     
2.1.4 Peptides and primers  
All listed peptides were produces at the Genomics & Proteomics Core Facility of the 
German Research Center (Heidelberg) 
Protein  Peptide Sequence 
SV40 tag 362–384 TNRFNDLLDRMDIMFGSTGSADI 
 560–568 SEFLLEKRI 
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All listed primers were purchased from Thermo Fisher Scientific GmbH (Dreieich). 
Primer name  Sequence (5’ → 3’)  
Tag1  GGA CAA ACC ACA ACT AGA ATG CAG  
Tag2  CAG AGC AGA ATT GTG GAG TGG 
ACH-1 CCA GAT TGC AGT TAT GAG GAC AGC 
ACH-2 CTT GAC TAG TAT TAG CTT GGT CCC AGA GC 
TGB-1 CCC TCA TTG TCC CAG AGG GAG CCA TGA C 
TGB-2 CCC CCT CCG AAT GTG AGC TTG GCA CCT GC 
 
2.1.5 Primary antibodies  
2.1.5.1 Antibody reactivity: human 
Name Host Clonality Supplier, cat# 
ADAM15 goat pab R&D Systems, AF935 
MAdCAM1 goat pab Santa Cruz Biotech, sc-16004 
Integrin beta1 mouse mab Santa Cruz Biotech, sc-9970 
Integrin beta7 rabbit pab Santa Cruz Biotech, sc-15330 
Tissue Factor mouse mab Calbiochem, 612161  
CD6 mouse mab Santa Cruz Biotech, sc-7320 
TECK goat pab R&D Systems, AF334 
Flt1 rabbit pab Neomarkers, RB-1527-P0 
E-Selectin goat pab Santa Cruz Biotech, sc-6937 
HCAM rabbit pab Santa Cruz Biotech, sc-7051-R 
ICAM1 rabbit pab Santa Cruz Biotech, sc-7891 
ICAM2 goat pab Santa Cruz Biotech, sc-1512 
CD107a mouse mab BD Biosciences, 555798 
VCAM1 mouse mab Santa Cruz Biotech, sc-52620 
P-Selectin rabbit pab USBiological, C2415-04A 
ALCAM goat pab Santa Cruz Biotech, sc-8548 
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2.1.5.2 Antibody reactivity: Simian Virus 40 
Name Host Clonality Supplier, cat# 
SV40 Tag rabbit pab Santa Cruz Biotech, sc-20800 
 
2.1.5.3 Antibody reactivity: Murine 
Name Host Clonality Supplier, cat# 
MAdCAM1 rat mab Santa Cruz Biotech, sc-19604 
E-Selectin rabbit pab Santa Cruz Biotech, sc-14011 
ICAM1 rat mab Santa Cruz Biotech, sc-52553 
VCAM1 rat mab AbD Serotec, MCA2297 
P-Selectin goat pab Santa Cruz Biotech, sc-6941 
CD31 Rat  IgG2a BD Biosciences, 550274 
FoxP3 rat IgG2a eBioscience, 14-5773 
CD4 rat IgG2a BD Biosciences, 553647 
CD8 Alpha rat mab AbD Serotec, MCA1108XZ 
CD3-e goat pab Santa Cruz Biotech, sc-1127 
 
2.1.6 Secondary antibodies 
Reactivity Conjugate Host Format Supplier, cat# 
hamster IgG DyLight®549 goat F(ab')2 AbD Serotec,  STAR104D549 
rabbit IgG Alexa Fluor® 488 chicken Whole ab Invitrogen, A-21441 
rabbit IgG Alexa Fluor® 594 chicken Whole ab Invitrogen, A-21442 
goat IgG Alexa Fluor® 488 chicken Whole ab Invitrogen, A-21467 
goat IgG Alexa Fluor® 594 chicken Whole ab Invitrogen, A-21468 
rat IgG Alexa Fluor® 594 chicken Whole ab Invitrogen, A-21471 
 
2.1.7 Mice 
RT5 mice (kindly provided by N. Garbi, German Cancer Research Center, Heidel-
berg, Germany) express the SV40 T Antigen (Tag) under control of the rat insulin 
promoter (RIP) (Hanahan, 1985) and have been generated in the C3HeB/Fe back-
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ground. Tag expression in RT5 mice starts at 10 weeks of age and leads to the for-
mation of insulinomas and premature death at ~30 weeks. In indicated experiments, 
the F1 generation of RT5/C3H mice was used.  
Mice transgenic for a TCR that recognizes Tag presented by the MHC class I mole-
cule H2-Kk (kindly provided by N. Garbi, German Cancer Research Center, Heidel-
berg, Germany) are referred to as TCRCD8. TCRCD8 mice have been backcrossed 
on the C3HeB/Fe background and are maintained as a homozygous colony.  
TagTCR1 mice bear a transgenic TCR specific for the SV40 T Ag (Forster and Lie-
beram, 1996). TagTCR1 mice express the H2-ABk-restricted TCR for Tag (kindly pro-
vided by N. Garbi, German Cancer Research Center, Heidelberg, Germany) and 
have been backcrossed on the C3HeB/Fe strain for ~30 generations. Peripheral lym-
phocytes represent 10% transgenic CD4 positive T cells with a normal CD4:CD8 T-
cell ratio.  
NOD/Scid mice were purchased from Charles River WIGA (Sulzfeld, Germany). 
All mice were kept under specific pathogen-free conditions at the German Cancer 
Research Center. Animal experiments were approved and authorized by local gov-
ernment. Experiments were performed with 6- to 12-week-old mice, unless otherwise 
stated.  
 
2.1.8 Equipments 
Product Source of supply  
Biological Safety Cabinet   SterilGARD Hood Baker, Stanford, USA 
Centrifuge (Minifuge T) Heraeus, Hanau, Germany  
FACS Calibur   Becton Dickinson, Heidelberg, Germany  
FACS Canto II   Becton Dickinson, Heidelberg, Germany  
Freezer (-20°C)   Liebherr, Ochsenhausen, Germany  
Freezer (-80°C) Forma Scientific, USA 
Glass Pipettes   Hirschmann, Eberstadt, Germany  
Glassware Schott, Mainz, Germany 
Incubator   Nuaire, Plymouth, USA  
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Product Source of supply  
Magnetic Particle Concentrator    Dynal, Hamburg, Germany  
Micropipettes (2-1000 µl)   Gilson, Bad Camberg, Germany   
Milli-Q Water Purification Device   Millipore, Eschborn, Germany  
Multichannel Pipettes (8, 12 channels)   Rainin, Leiden, Netherlands    
Neubauer counting chamber (0.1 mm)   Brand, Wertheim, Germany    
OneTouch Ultra 2 LifeScan, Neckargemünd, Germany 
TM separator   Miltenyi Biotech, Bergisch Gladbach, 
Germany  
Pipetboy Brand, Wertheim, Germany  
Axioplan 2 Microscope Carl Zeiss, Jena, Germany 
Leica CM3050s cryo-microtome Leica Microsystems, Wetzlar, Germany 
Refrigerator   Liebherr, Ochsenhausen, Germany  
Roller-mixer RM5   Karl Hecht GmbH, Sondheim, Germany     
Spectrophotometer Titertek  Labsystems, Helsinki, Finland  
Tabletop centrifuge   Heraeus, Hanau, Germany  
Vortexer (Reax 2000)   Heidolph, Schwabach, Germany  
Water bath (SW21)   Julabo, Seelbach, Germany 
 
2.1.9 Software  
Product Source of supply  
CELLQuest Pro (4.02) Becton Dickinson, Heidelberg, Germany  
FACS Diva  Becton Dickinson, Heidelberg, Germany  
FlowJo (6.2)   Tree Star, San Carlo, USA  
Graphpad Prism 5   GraphPad Software Inc., San Diego, USA  
Windows XP   Microsoft, Redmond, USA  
Office 2003   Microsoft, Redmond, USA 
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2.2 Methods 
2.2.1 Murine studies 
2.2.1.1 Adoptive Transfer 
Donor T cells for adoptive transfers were derived from Tag-TCR1 and TCRCD8 mice. 
To isolate CD4 positive TCRtg T cells lymph nodes of Tag-TCR1 mice at the age of 6-
8 weeks were used. The animals were sacrificed by cervical dislocation and inguinal, 
mesenteric, brachial, axillary and superficial cervical lymph nodes were excised in a 
sterile environment and kept in RPMI-1640 on ice until further use. To isolate CD8 
positive TCRtg T cells the spleen of TCRCD8 mice at the age of 6-8 weeks was 
used. The animals were sacrificed by cervical dislocation and the spleen was excised 
in a sterile environment and kept in RPMI-1640 on ice until further use.  
Lymph nodes and spleen were minced using a scalpel and the tissue fragments were 
placed into the cell strainer. Using the plunger end of the syringe, the respective tis-
sue fragments were pressed through the cell strainer into a petri dish. The cell 
strainer was rinsed with 5mL RPMI-1640 and discarded. The suspended cells were 
transferred to a 15mL conical centrifugation tube and spun at 800xg for 3 minutes. 
The supernatant was discarded and the cell pellet resuspended in 1mL ACK lysis 
buffer. After incubation at RT for 5-10 minutes 9mL RPMI-1640 was added and the 
tube was spun as before. The supernatant was again discarded and the pellet resus-
pended in 3mL RPMI-1640. Finally the cells were counted using a hemocytometer. 
Of the respective cell suspension 1.5 x 107 cells per six-well plate were cultured in 
RPMI-1640 medium supplemented with 10% FCS, 2 nM glutamine, 100 U/ml penicil-
lin, 100 µg/ml streptomycin, 0.05 mM 2-ME, and 10 U/ml of rIL-2. TagTCR1 lymph 
node cell cultures received 25 nM Tag peptide 362–384 and TCRCD8 splenocytes 
received 25 nM Tag peptide 560–568. Cultures were incubated for 72h.  
Ten days after irradiation, 5.0 x 106 in vitro activated TagTCR1 cells or TCRCD8 cells 
were injected intravenously or intraperitoneally in RT5 mice or NOD/Scid mice. 
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2.2.1.2 Organ removal  
Seven days after adoptive transfer of T cells animals were sacrificed by cervical dis-
location. The abdominal region was disinfected with 70% ethanol and the organs 
were removed under aseptic conditions. For histology all organs were frozen in Tis-
sue-Tek O.C.T. embedding medium and stored at -80°C.  
 
2.2.1.3 Anesthesia of mice  
Anesthesia was used to produce a surgical level of anesthesia lasting 15-30 minutes 
and sedation of 1-2 hours. To produce 10ml anesthetic mixture consisting of 100mg 
ketamin and 10mg xylazine, 4 ml KETANEST S (concentration 25 mg/ml, Pfizer 
Pharma GmbH, Berlin) and 0.5 ml Rompun 2% (concentration 20mg/ml, Bayer 
HealthCare, Leverkusen) were mixed with 5.5 ml PBS. Using a syringe (1 ml) and a 
needle (23-25 gauge 5/8 inch) 0.1ml per 10 gm of body weight were injected intrap-
eritoneally. 
 
2.2.1.4 Animal irradiation 
At an age of 24 weeks RT5 mice were anesthetized and irradiated with 0.5, 1, 2, or 6 
Gy from a Gammatron Cobalt 60 therapy unit (Siemens, München, Germany) at a 
dose rate of 0.4 Gy/min. Irradiation was directed against the visceral region by shield-
ing caudal and cranial areas of the animal using a lead apron with 3mm thickness. 
Subcutaneous tumors in NOD/Scid mice were irradiated with a dose of 2 Gy using 
the same therapy unit. 
 
2.2.1.5 Surgical procedures 
Mice were anesthetized to attain a surgical level of anesthesia. The anesthetic effect 
was verified by checking the plantar reflexes. The operation area was prepared by 
washing the surgical and adjacent area with 70% ethanol. The fur of mice was re-
moved using a razor and the surgical area was carefully cleaned using 70% ethanol. 
All surgical procedures were performed in a sterile environment. 
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Experimental splenectomy in the mouse: At the left hypochondrium a 1.5 cm long 
incision was made using surgical scissors through skin and peritoneum. The spleen 
was lifted gently using blunt-ended forceps until the hilum was visible. A single knot 
was used to tie off the artery with absorbable monofilament suture (MonoPlus, 
B.Braun, Germany) by looping the suture through the mesentery, thereby ligating the 
artery that enters the spleen at the superior polus. Another single knot was made to 
tie off the efferent venule, which exits the spleen at the inferior polus. Connective tis-
sue was cut away and the spleen was removed. The peritoneum was closed using 
absorbable monofilament suture (MonoPlus, B.Braun, Germany). The skin was 
closed using Ethicon Mersilene 3-0 suture (Johnson & Johnson, Neuss, Germany).  
After the operation the animals were left to rest for 7 days. 
Tumor allografts: Multiple tumors from RT5 mice were excised in a sterile environ-
ment and separated from non-malignant tissue in RPMI-1640 on ice using a scalpel. 
NOD/Scid mice were anesthetized, a dorsal skinfold was formed with blunt-ended 
forceps and a 1.5 cm incision was made using surgical scissors through the skin. 
Forceps were used to form a pocket under the skin and a single tumor was inserted. 
The skin was closed using Ethicon Mersilene 3-0 suture (Johnson & Johnson, Neuss, 
Germany). 
After the operation the animals were monitored regularly for tumor growth. Mice bear-
ing tumors which outgrew to a volume bigger than 64 mm3 were selected for the irra-
diation protocol with a dose of 2 Gy and infusion of TCRtg CD8 positive T cells. 
1400W slow release mini-osmotic pumps: The iNOS inhibitor 1400W (N-[[3-
(Aminomethyl)phenyl]methyl]-ethanimidamide dihydrochloride) (Tocris Bioscience, 
United Kongdom) was used at a concentration of 240 µg/µl in PBS, 200µl of the solu-
tion were filled into a ALZET mini-osmotic pump model 2002 (ALZET Osmotic 
Pumps, Cupertino, USA) which provided a flow rate of 0.5 µl/h. This resulted in a 
dose of 144 mg/kg/d (= 6mg/kg/h) over the duration of 2 weeks. 
Filling the pump was accomplished with a small syringe (1.0 ml) and the provided 
blunt-tipped, 27 gauge filling tube. First, the solution was drawn into the syringe and 
the filling tube was attached. Then, the filling tube was inserted through the opening 
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at the top of the pump and the pump was filled. Excess solution was wiped off and 
the flow moderator inserted until the white flange was flush with the top of the pump. 
Once the animals were anesthetized, and prepared for surgery, a 1.5 cm wide mid-
scapular incision was made using a scalpel, which allowed placing the pump on the 
dorsal side of the animal. A hemostat was inserted into the incision and the subcuta-
neous tissue was spread to create a 2.5 cm long pocket for the pump. A filled pump 
was inserted into the pocket, with the delivery portal first to minimize interaction be-
tween the compound and the healing of the incision. The skin was closed using Ethi-
con Mersilene 3-0 suture (Johnson & Johnson, Neuss, Germany). 
 
2.2.1.6 Administration of CLIP 
Clodronate was a gift from Roche (Roche Diagnostics GmbH, Mannheim, Germany) 
and was encapsulated in liposomes (kindly conducted by N. van Rooijen, VUMC, 
Amsterdam, The Netherlands) to create CLIP. For the construction of control lipo-
somes, PBS was encapsulated. Other reagents for preparation of liposomes were 
phosphatidylcholine (Lipoid GmbH, Ludwigshafen, Germany) and cholesterol (SIGMA 
Chem.Co. USA). For long term administration of CLIP, intra-peritoneal injections were 
given every 5 days. For the first injection 200µl were applied, the following injections 
used 100µl each. 
 
2.2.2 Methods of molecular biology  
2.2.2.1 Isolation of chromosomal DNA  
Mouse tail biopsies from 3 week old animals were digested for 2 hours with 0.2 
mg/ml Proteinase K in tail buffer at 55°C. The suspension was diluted with 300µl 
ddH2O and the samples were boiled at 95 °C for 5 minutes. The samples were 
cooled down to room temperature and cellular debris was removed by centrifugation 
(13.000 rpm/10 min). From the supernatant 3 µl were used as template for the PCR 
amplification. 
 
MATERIALS AND METHODS 
Page |  37 
2.2.2.2 PCR amplification of genomic DNA  
The polymerase chain reaction (PCR) was used to amplify a DNA sequence from the 
transgene of interest, which is specific for every mouse strain used. Repeated cycles 
of melting, annealing and synthesis lead to exponential amplification respective se-
quence. 
The reaction mix was set up as follows: 
Reagent Volume Final concentration 
dNTP-Mix (2.5 mM each) 4.0 µl 0.2 mM 
Primer βm1 (100 pmol/µl) 0.2 µl 0.4 pmol/µl 
Primer βm2 (100 pmol/µl) 0.2 µl 0.4 pmol/µl 
Taq Polymerase (5 units/µl) 0.5 µl 0.05 units/µl 
5x reaction buffer 10.0 µl 1x 
MgCl2 (50 mM) 2.5 µl 2.5 mM 
DNA Template 3.0 µl  
ddH20  ad 50 µl  
 
The PCR program mix was set up as follows: 
Step Time Temperature  
I) Denaturation 60 sec 94°C  
II) Annealing 30 sec 60°C  
III) Elongation 120 sec 72°C  
Go to step I; 35 cycles    
IV) Finalizing 10 min 72°C  
  
2.2.2.3 Analytical agarose gel electrophoresis  
Separation of the DNA fragments according to their size was carried out in a 1.5 % 
Agarose gel (0.2 µg/ml ethidiumbromid) in TAE buffer using an electric field. 10 µl of 
the PCR product were used, a standard 100 bp DNA ladder allowed evaluation of 
DNA fragment size. UV-irradiation at 280 nm of the gels was used to detect fluores-
cent DNA bands. 
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2.2.3 Cell culture methods 
All types of cells were cultivated in sterile incubators at 37°C with a CO2-
concentration of 5% (v/v). 
2.2.3.1 Isolation and culture of human microvascular endothelial cells 
Microvascular endothelial cells were isolated from samples of pancreatic tumors. Tis-
sue samples were washed in phosphate-buffered saline (PBS; Invitrogen, Karlsruhe, 
Germany), minced mechanically into small pieces (~3 mm2), and resuspended with 
endothelial cell basal medium (ECBM) + supplement. The suspension was filtered 
using 40-µm cell strainers (Falcon BD, Heidelberg, Germany), and the resulting cells 
and cell aggregates were washed with PBS. Endothelial cells were magnetically iso-
lated from this cell population using anti–CD31-Dynabeads (Dynal). Isolated endo-
thelial cells were used immediately or transferred to gelatin-coated (2%) cell culture 
flasks (Biochrom) and cultured in supplemented ECBM until passage three. During 
endothelial cell culture, endothelial cells derived from primary pancreatic carcinomas 
were supplemented with 50 µg/mL of autologous tumor cell lysate to maintain the 
tumor endothelial phenotype during culture. Tumor tissue lysates were prepared by 
mechanical homogenization using an Ultra-turrax T8 disperser (IKA, Werke Staufen, 
Germany). Tumor lysates were centrifuged (20 minutes at 30000g) to remove cell 
debris and organelles. Protein concentrations of the lysate supernatants were deter-
mined by Bradford assay (BioRad, München, Germany). Endothelial cells were al-
ways washed carefully with PBS to remove traces of cell lysates before use in sub-
sequent experiments. 
 
2.2.3.2 Quantification of viable cells  
A Neubauer hemocytometer was used for the quantification of viable cells. The re-
spective cell suspension was mixed with an equal volume of trypan blue [0.4% (w/v) 
tyrypan blue in PBS] and filled into the chamber. The counting chamber was then 
placed on the microscope stage and the counting grid was brought into focus at low 
power. Viable cells remained opaque and were counted in the 1mm center square 
and the four corner squares.   
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Each square of the hemocytometer represents a total volume of 10-4 cm3. Since 1 
cm3 is equivalent to 1 ml, the subsequent cell concentration per ml was determined 
using the following calculation: 
Cells / ml = count per square x the dilution factor x 104  
 
2.2.3.3 Passage of adherent cells 
When confluence was reached, adherent cells were passaged under sterile condi-
tions. After the removal of cell culture medium, cells were washed with Dulbecco´s 
PBS and detached from the flask by adding EDTA/trypsin. The reaction was 
quenched with RPMI-1640 + 10% (v/v) FCS after 5 minutes of incubation at 37°C. 
The detached cells were spun down at 1400 rpm for 10 min, the pellet was resus-
pended in endothelial cell basal medium + supplement and finally distributed to 3 tis-
sue culture flasks. 
 
2.2.4 Immunological methods 
2.2.4.1 Flow cytometry 
Single-cell suspensions of tumor tissue (107 cells per well) were blocked with poly-
clonal human immunoglobulins (Endobulin, 2.5 mg/mL; Baxter Oncology, Frankfurt, 
Germany) and incubated with one of the following anti-human antibodies: beta1 in-
tegrin (1:100); or beta7 integrin (1:100), E-selectin (1:100), ICAM1 (1:100), ICAM2, 
MAdCAM1 (both 1:100), CD166 (1:100), CD6 (1:100); P-selectin (1:200); or VCAM1 
(1:100) for 30 minutes on ice. Antibodies were detected by respective chicken anti-
mouse, chicken anti-goat, or chicken anti-rabbit secondary antibodies (1:400). Dead 
cells, which were labeled with 1 µg/mL of propidium iodide immediately before flow 
cytometry, were excluded from analysis. Recordings were made from at least 1.0 x 
105 cells on a FACS-Calibur and FACS-Canto II flow cytometer using FlowJo 6.2 
software. 
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2.2.4.2 Immunohistochemistry  
For histological analysis organs were snap-frozen in liquid nitrogen and cryosections 
of 5 µm thickness were produced using a cryotome. Sections were transferred to 
glass slides, air dried and fixed in ice-cold aceton for 10 min. Sections were used 
immediately after fixation for immunostaining.  
A water repellant wax pen (DAKO pen) was used to create a boundary around the 
tissue sections on the glass slide. The immunostaining procedure was performed in a 
dark, humid staining chamber. Sections were rehydrated in PBS for 10 min and Fc 
receptors were saturated by blocking for 20 min with 1% normal chicken serum solu-
tion. Sections were incubated for 45 minutes with 100 µl of one of the following di-
luted detection antibodies each: CD31, FoxP3, CD4, CD8, CD3 or SV40 Tag (all 
1:50). Subsequently the tissue sections were washed 3 times for 3 min in PBS. 
Fluorophore-conjugated secondary antibodies were diluted 1:200 in PBS and incu-
bated for 45 minutes on the tissue sections with 100 µl each. Thereafter the sections 
were washed 3 times for 3 min in PBS. Finally the sections were mounted in glycerol 
gelatin and cover slips were mounted on the slides. 
 
2.2.5 Statistical Analyses 
P values were calculated by using two-sided Student's t test; for survival calculations 
Log-Rank tests were used. P less than .05 was considered to be statistically signifi-
cant. Tumor growth experiments were tested using Spearman's rank correlation. 
Given the monotonic relation of age and blood glucose in this mouse model and a 
total of 16 XY pairs, a threshold value of r was set at -0.5 to indicate a significant dif-
ference in the course of blood glucose decrease. 
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3 Results 
3.1 In vitro response to LD radiation 
3.1.1 LD irradiation response of human tumor derived HPMEC 
Endothelial cells are the first barrier of activated tumor-specific T cells that home to 
tumors (Buckanovich et al., 2008). In many tumors the malignant cells drive the en-
dothelium into constant angiogenesis by secretion of angiogenic factors which finally 
induce endothelial cell anergy (Fukumura et al., 1998; Griffioen et al., 1999). Thus, T 
cells are unable to transmigrate into the tumor parenchyma to perform their effector 
functions such as release of anti-angiogenic cytokines or lysis of tumor cells. Since it 
was reported that irradiation can induce an inflammatory tumor environment allowing 
adoptively transferred T cells to transmigrate into the tumor (Ganss et al., 2002), di-
rect irradiation of pancreatic tumor derived HPMEC (human primary microvascular 
endothelial cells) was performed to elucidate the role of radiation induced changes in 
expression patterns of endothelial factors associated with leukocyte transmigration. 
Pancreatic tissue from patients with histologically confirmed primary pancreatic carci-
noma was collected during pancreatectomy. HPMEC were isolated from resected 
tumor tissue as described (Nummer et al., 2007) and expanded for 4 passages. Addi-
tionally, primary endothelial cells from human umbilical vein (HUVEC) were expanded 
for 4 passages and incubated with tumor lysate from pancreatic carcinoma patients. 
Both cell types were allowed to divide until 90% confluency was reached. Subse-
quently, cells were subjected to irradiation doses from a linear accelerator from 0.5 
up to 6 Gy in a sterile container and analyzed by flow cytometry after 4 hours, 18 
hours, 1 day or 2 days, respectively. Cell Culture medium was not changed to leave 
growth factor levels undisturbed. The frequencies of cells double-positive for the en-
dothelial cell marker CD31 and ADAM15, MAdCAM1, Integrin β1, Integrin β7, Tissue 
Factor, CD6, CCL25, Flt-1, CD62E, HCAM, ICAM1, ICAM2, CD107a, VCAM1, 
CD62P or ALCAM were measured.  
Radiation induced cell apoptosis as detected by flow cytometric measurement of cell 
shape and granularity was not significant for irradiation doses less than 3 Gy, but de-
tectable after irradiation using a dose of 3 Gy (36% of all cells) or 6 Gy (61% of all 
cells) (not shown). Figure 1 depicts a representative LD irradiation response of the 
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expression profile of ICAM1 in HPMEC from one pancreatic carcinoma patient. The 
frequency of double positive endothelial cells depends on both the irradiation dose 
and the time point of analysis. The numbers of ICAM1 expressing cells increased in 
the unirradiated fraction until one day after treatment and then stabilized at that level, 
an artificial phenomenon that relies on deprivation of medium growth factors and 
overgrowth of the plastic surface. Therefore, for all following experiments the time 
point of analysis at 2 days after irradiation was chosen. With regard to irradiation de-
pendency, ICAM1 expression increased (21% or 18%, respectively) at day 2 when 
irradiated with 3 or 6 Gray compared to the unirradiated fraction demonstrating the 
activating effect of LD irradiation on human tumor derived microvascular endothelial 
cells. 
 
3.1.2 LD irradiation induces human tumor derived HPMEC to specifi-
cally upregulate lymphocyte transmigration associated molecules  
To study the influence of irradiation on tumor vasculature, primary endothelial cells 
were cultured from pancreatic cancer patient derived tumors. Since it is well-known 
that even genetically normal primary cells placed in cell culture quickly lose their dif-
ferentiated gene expression pattern and phenotype (Mooney et al., 1992), tumor mi-
croenvironment was mimicked by adding tumor lysate from each tumor to the respec-
tive cultures. Figure 2 summarizes the irradiation induced effects in HPMEC. 
Significant differences could be detected in the expression patterns of P-selectin and 
the Ig-superfamily cell adhesion molecules ICAM1, ICAM2, MAdCAM1, VCAM1 and 
ALCAM. Interestingly, significantly higher frequencies of both ICAM1 and ICAM2 ex-
pressing cells were observed when treated with the highest irradiation dose (6Gy) 
and when treated with an intermediate dose of 2Gy. Significantly higher frequencies 
of VCAM1 and ALCAM expressing cells were observed when cells were treated with 
the highest irradiation dose (6Gy) and when treated with an intermediate irradiation 
dose of 1Gy. Additionally, numbers of ALCAM expressing cells were increased after 
3Gy irradiation. The frequencies of both MAdCAM1 and P-selectin expressing cells 
were increased only when cells were treated with the highest irradiation dose (6Gy). 
For all increased expression patterns that were observed, treatment with the highest 
dose of 6Gy showed the strongest effect, the effect of the intermediate dose was 
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weaker. In summary, in human tumor derived HPMEC many molecules associated 
with lymphocyte transmigration displayed a differential activation pattern after LD ir-
radiation. 
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Figure 1. Representative LD irradiation response of ICAM1 in 
HPMEC. HPMEC were isolated from one resected pancreatic 
carcinoma tissue as described. After cultivation to sub-
confluent cell layers, HPMEC were subjected to irradiation 
doses of 0.5, 1, 2, 3 or 6 Gy and analyzed by flow cytometry 
after 4 [blue], 18 [magenta], 24 [yellow] or 42 [cyan] hours for 
the expression of CD31 and ICAM1. The frequency of double-
positive cells is shown. 
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Figure 2. LD irradiation response of endothelial cell molecules in HPMEC. After culti-
vation to sub-confluent cell layers, HPMEC (n=4) were analyzed untreated or treated 
with irradiation doses of 0.5, 1, 2, 3  or 6 Gy and analyzed by flow cytometry after 2 
days for the expression of CD31 and one of the indicated molecules. The difference 
in frequency of double-positive cells between untreated and irradiated cells is shown.  
** P < 0.05; * P < 0.1 (two-tailed Student's t-test) 
 
3.1.3 HUVEC display minimal responsiveness to LD irradiation treat-
ment 
Additionally to human tumor derived HPMEC, a different source of endothelial cells 
was used in order to analyze the impact of LD irradiation on a non-tumorous endo-
thelial cell subset. HUVEC are cultured from cord of newborns and are widely used 
as a model for endothelial cell functions. However, the properties of untreated 
HUVEC do not represent the responses in physiopathology and toxicity related to the 
different types of endothelial cells found in an organism, especially tumor derived mi-
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crovascular cells. Therefore, HUVEC were pulsed with tumor lysate since it was 
demonstrated that this treatment induces an adhesion molecule expression pattern in 
part resembling that of tumor derived microvascular cells (Nummer et al., 2007), 
making them better suited for studies of irradiation dependant adhesion molecule 
expression studies. 
There was no detectable ICAM1 expression in HUVEC whether treated with irradia-
tion or not (figure 3). Expression on more than 10% of all cells was limited to VCAM1 
and Integrin beta 1. VCAM1 was upregulated in HUVEC pulsed with tumor lysate in 
39% of the cells but not in unpulsed cells (not shown). The frequency of VCAM1 ex-
pressing cells decreased with an irradiation dose of 1Gy to 14% of the cells but not 
with any other dose. Integrin beta 1 was upregulated in HUVEC pulsed with tumor 
lysate in 51% of the cells. Irradiation induced expression of Integrin beta 1 on more 
than 79% of all cells, regardless of the irradiation dose. All other molecules analyzed 
showed expression on less than 10% of all cells and were expressed independently 
of irradiation treatment without statistically relevant variations. Taken together, 
HUVEC showed only minimal responsiveness to irradiation treatment.  
 
3.2 Combination treatment using LD radiation and Immuno-
therapy 
3.2.1 Local LD irradiation affects tumor microvessel morphology and 
cell adhesion molecule expression 
Due to the change in adhesion molecule expression on human tumor derived 
HPMEC upon low dose irradiation (figure 2), it was hypothesized that locally applied 
low dose irradiation was sufficient to create a niche favoring immune effector cell 
entry to a tumor without inducing toxic side effects. To test this hypothesis in vivo, the 
RIP1-tag5 (RT5) mouse model was chosen for its ability to spontaneously develop 
non-tolerogenic tumors. Several irradiation doses were tested for their effectiveness 
to activate tumor endothelium in vivo. This was accomplished by LD irradiation of 
whole tumors by abdominal radiation treatment of RT5 mice. Tumors were excised 
after 1 week and analyzed by immunohistochemistry for the expression of the 
endothelial marker CD31 and P-selectin, E-selectin, ALCAM, VCAM1, ICAM1 or 
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MAdCAM1. The expression levels of E-/P-selectin and all the Ig-superfamily cell 
adhesion molecules but CD31 were lower than the detection limit of fluorescence 
microscopy (not shown). CD31 positive endothelial cells were analyzed by computer 
assisted measurement in the tumor and in normal surrounding pancreatic tissue for 
the total area, the mean diameter and the mean expression level of CD31 (figure 4). 
Tumor microvessel morphology and expression of the cell adhesion molecule CD31 
was affected compared to irradiated normal tissue when tumors were irradiated with 
a dose of 6 Gy but not with 2 Gy. Irradiation rendered endothelial cells in tumors 
longer, the total area of the tissue covered by endothelial cells in tumors increased 
and the expression level of CD31 of tumor endothelial cells increased compared to 
endothelial cells from irradiated normal tissue.  
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Figure 3. LD irradiation response of endothelial cell molecules in tumor lysate 
treated HUVEC. After cultivation to sub-confluent cell layers, HUVEC (n=4) were 
analyzed untreated [0, blue] or treated with irradiation doses of 0.5 [magenta], 1 [yel-
low], 2 [cyan], 3 [lilac] or 6 Gy [orange] and analyzed by flow cytometry after 2 days 
for the co-expression of CD31 and one of the indicated molecules. The frequency of 
double-positive cells is shown.  
* P < 0.05 (two-tailed Student's t-test) 
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Figure 4. LD irradiation response of endothelial cells in insulinomas. Tumors and 
normal pancreatic tissue of RT5 mice (n=8) were left untreated or were treated with 
irradiation doses of 2 or 6 Gy, excised after one week and analyzed by immunohisto-
chemistry for the expression of CD31. (A) Single immunofluorescence pictures were 
assembled into one image per tumor. CD31 positive endothelial cells were analyzed 
for (B) the fraction of total tissue area, (C) their mean diameter, and (D) the mean 
fluorescence intensity (MFI) of the molecule CD31 by computer assisted measure-
ment.  
* P < 0.05; (two-tailed Student's t-test). Color coding for mean diameter in (A): red 
<80 µm, green 80-120 µm, yellow 120-160 µm, blue 160-200 µm, turquoise 200-240 
µm, lilac 240-280 µm, white >280 µm [cut-off] 
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3.2.2 Local LD irradiation renders solid RT5 tumors accessible for host 
T cell infiltration 
Tumor-specific host T cells can be found in RT5 mice, since expression of the onco-
gene begins in adult life and leads to autoimmunity and lymphocytic infiltration of 
premalignant lesions (Ganss and Hanahan, 1998). To investigate whether LD irradia-
tion alone does affect recruitment of host T cells to the tumor although no direct evi-
dence was obtained about an increased activation of tumor microvessels after LD 
irradiation, the same tumors were analyzed for infiltrating T cell subsets (figure 5). 
Unirradiatetd tumors showed only base line levels of T cell infiltration. Significantly 
higher numbers of both CD3 positive T cells and FoxP3 positive T regulatory cells 
were found in irradiated tumors. However, this was observed only after irradiation 
with 0.5 Gy, whereas all other doses did not show this effect. Although local LD irra-
diation made solid RT5 tumors accessible to tumor-specific host T cell infiltration, the 
frequencies of infiltrated T cells were low, probably because activation of tumor endo-
thelium could not be induced as indicated before by the lack of upregulation of 
transmigration relevant molecules.  
It has been demonstrated that immunotherapeutic treatment of tumors in a murine 
tumor model system could only induce significant expression of ICAM and VCAM on 
tumor endothelium when radiation therapy and T cell transfer were combined, but not 
with either regimen alone (Quezada et al., 2008), suggesting that infiltrating T cells 
could be an important factor in further increasing tumor vessel activation.  Therefore, 
a therapeutic approach using a combination of local LD irradiation and adoptive 
transfers of tumor-specific T cells was employed to induce T cell infiltration and de-
struction of RT5 tumors. 
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Figure 5. Tumor infiltration by host T cells after LD irradiation. Tumors of RT5 mice 
(n=8) were left untreated or were treated with irradiation doses of 0.5, 1, 2 or 6 Gy, 
excised after one week and analyzed by immunohistochemistry for CD3 (white bar), 
CD4 (blue bar) and CD8 positive (red bar) T cells (A) and for CD3 FoxP3 double 
positive Treg (B). A representative immunohistochemical staining of Treg is depicted 
in panel C and D, the former showing a phase contrast and the latter showing a fluo-
rescence image (red: FoxP3, green: CD3). 
* P < 0.05; (two-tailed Student's t-test). 
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3.2.3 Combination of local LD irradiation and transfer of tumor-specific 
T cells into tumor-bearing hosts induces massive T cell infiltra-
tion of RT5 tumors 
T cell receptor transgenic (TCRtg) CD4 and CD8 positive T cells specific for the sur-
rogate tumor antigen SV40 Tag were recovered from spleen and lymph nodes of do-
nor mice and activated in vitro using IL-2 and feeder cells pulsed with MHC class I 
and class II restricted peptides (figure 6). Pre-activated T cells were adoptively trans-
ferred 10 days after LD irradiation treatment of RT5 animals. Tumors were excised 1 
week after T cell transfer and analyzed by immunohistochemistry for the infiltration of 
CD3 positive T cells, CD4 positive T cells, CD8 positive T cells and CD3 FoxP3 dou-
ble-positive T regulatory cells (Treg). Transfer of either CD4 or CD8 positive T cells 
without irradiation treatment resulted in higher numbers of T cells in the tumors than 
in untreated mice (figure 7 A, B); the frequency of CD4 positive T cells increased to 
3 times the base line infiltration (32 vs. 13 cells per area), the frequency of CD8 posi-
tive cells increased to 9 times the base line infiltration (219 vs. 24 cells per area). 
When mice were subjected to irradiation treatment in combination with T cell transfer 
an additional boost of T cell infiltration for both transfer groups was detected; the fre-
quency of CD4 positive cells increased up to 3 times the frequency in the unirradi-
ated group (101 vs. 32 cells per area), the frequency of CD8 positive cells increased 
up to 3 times the frequency in the unirradiated group (701 vs. 219 cells per area). 
Additionally to the increased infiltration of the transferred T cell fraction, concomitant 
infiltration was observed, leading to high numbers of total CD3 positive T cells. The 
strongest total T cell infiltration was observed when CD4 or CD8 positive T cells were 
transferred into mice locally irradiated with a dose of 1 Gy, respectively (920 or 200 
cells per area).  
Concomitant tumor infiltration of CD4 positive host T cells after transfer of CD8 posi-
tive TCRtg T cells was most pronounced in the case of radiation treatment of RT5 
mice with 0.5, 1 or 2 Gy (figure 7 D). Numbers of Foxp3 positive T regulatory cells 
were enhanced only when the lowest dose of 0.5 Gy was applied. Concomitant tumor 
infiltration of CD8 positive host T cells after transfer of CD4 positive TCRtg T cells 
was most pronounced when mice received radiation treatment of 1 or 2 Gy (figure 7 
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C). There was no enhanced infiltration of Foxp3 positive T regulatory cells in any of 
the settings after transfer of CD4 positive TCRtg T cells.  
The results of this study proved that the transfer of tumor-specific T cells into previ-
ously low-dose irradiated tumor-bearing hosts, which probably increased tumor ves-
sel activation as demonstrated in other studies (Ganss et al., 2002; Quezada et al., 
2008), is able to induce massive T cell infiltration of RT5 tumors. To assess the ca-
pacity of T cells to interfere with tumor growth, treatment response and survival were 
analyzed. 
 
3.2.4 Treatment response after massive T cell infiltration of RT5 tu-
mors is T cell subset dependent 
It was reported that after repeated adoptive transfers of TCRtg T cells into irradiated 
host RT5 mice reduced hemorrhages in the tumor mass can be observed and can be 
used as a measure of the treatment response (Ganss et al., 2002; Hamzah et al., 
2008). To investigate the treatment response in RT5 mice after LD irradiation and 
adoptive transfer of TCRtg T cells, tumors were excised, photographed and then pre-
served for immunohistological use. Representative photographs are depicted in 
figure 8B, showing a whole pancreas with two highly hemorrhagic tumors (blue ar-
rows) from the untreated control group in the upper panel and another pancreas with 
two non-hemorrhagic tumors (blue arrows) from the 2 Gy irradiated CD8 positive T 
cell transfer group in the lower panel. Transfer of TCRtg CD4 positive T cells into low-
dose irradiated RT5 mice resulted in a treatment response which was 10% for the 
animals that were irradiated with an intermediate dose (1 or 2 Gy, respectively), the 
other irradiation doses showed no difference compared to control. Transfer of TCRtg 
CD8 positive T cells into unirradiated RT5 mice alone resulted in 23% of all tumors 
becoming non-hemorrhagic, significantly higher values were obtained with irradiation 
doses of 1, 2 or 6 Gy (75%, 50% or 63%). Consequently, a single injection of TCRtg 
CD4 positive T cells can induce a mild treatment response and is not likely to inter-
fere with tumor growth, whereas a single injection of TCRtg CD8 positive T cells can 
induce a strong treatment response.  
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Figure 6. Local low dose irradiation protocol. (A) 24 weeks old RT5 mice were irradi-
ated with 0.5, 1, 2, or 6 Gy from a Gammatron therapy unit. Irradiation was directed 
against the visceral region by shielding caudal and cranial areas of the animal using 
a lead apron. Lymphocytes were isolated from lymph nodes or spleen of donor mice 
(TagTCR1, TCRCD8) and were cultured in medium supplemented with 10 U/ml of 
rIL-2. TagTCR1 lymph node cell cultures received 25 nM Tag peptide 362–384, 
TCRCD8 splenocytes received 25 nM Tag peptide 560–568. Cultures were incubated 
for 72h. (B) Ten days after irradiation, 5.0 x 106 in vitro activated TagTCR1 cells or 
TCRCD8 cells were injected i.v. or i.p (ADI). 
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Figure 7. Tumor infiltration by transferred TCRtg T cells (A, B) and concomitant infil-
tration by host T cells (C ,D). RT5 mice (A:n=13, B:n=22) were left untreated or were 
treated with local tumor irradiation doses of 0.5, 1, 2 or 6 Gy and received after 10 
days i.p. injections of TCRtg CD4 (A) and CD8 positive (B) T cells. Tumors were ex-
cised after one week and analyzed by immunohistochemistry for CD3 (white bar), 
CD4 (blue bar) and CD8 positive (red bar) T cells and for CD3 FoxP3 double positive 
Treg (black bar). 
* P < 0.05; (two-tailed Student's t-test).  
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Figure 8. Treatment response after local LD irradiation. RT5 mice (n=35) were left 
untreated or were treated with local tumor irradiation doses of 0.5, 1, 2 or 6 Gy and 
received after 10 days i.p. injections of TCRtg CD4 and CD8 positive T cells, respec-
tively. Tumors were excised after one week and analyzed for hemorrhages. The per-
centage of all non-hemorrhagic tumors is shown in A, panel B depicts two represen-
tative whole pancreata with hemorrhagic (top, arrows) and non-hemorrhagic tumors 
(bottom, arrows). 
* P < 0.05; (two-tailed Student's t-test). 
 
3.2.5 T cell infiltration of RT5 tumors does not depend on stimulation 
of lymphatic organs by irradiation 
Using the irradiation protocol established in this study in combination with T cell 
based immunotherapy of spontaneous tumors, highly infiltrated tumors were gener-
ated showing a strong treatment response already after administration of a single 
injection of TCRtg CD8 positive T cells. Irradiation of the whole pancreas with adja-
cent organs could however induce artifacts. Since the irradiated tissue area does 
contain non-malignant tissue and especially lymphatic tissue such as the spleen and 
lymph nodes control experiments have been conducted to exclude activation of lym-
phocytes in these organs. Local LD irradiation with a dose of 2 Gy was used in com-
bination with adoptive T cell transfer of TCRtg CD8 positive T cells to treat RT5 mice 
which have been splenectomized one week before treatment. Tumor infiltration by T 
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cells as read-out system was assessed using immunohistochemistry (figure 9). No 
significant differences were detected between the standard treatment of LD irradia-
tion with a dose of 2 Gy and adoptive T cell transfer of TCRtg CD8 positive T cells 
and the splenectomy group in terms of infiltration by CD3 positive T cells. To confirm 
that irradiation has to be focused only at the tumor and effects to other lymphatic tis-
sues such as lymph nodes are inconsequential, a subcutaneous allotransplant sys-
tem was established that allowed irradiation of the tumor without irradiating adjacent 
organs. In this system tumor fragments from RT5 mice were transplanted subcutane-
ously in NOD-Scid mice which were used because of their impaired T, NK and B cell 
function and because they fail to stimulate complement activity making them unable 
to reject an allotransplant. Multiple tumors from RT5 mice were excised and trans-
planted in NOD-Scid mice, from these 5 tumors continued to outgrow to a volume 
bigger than 64 mm3 and were selected for the irradiation protocol with a dose of 2 Gy 
and infusion of TCRtg CD8 positive T cells. The control group which was not irradi-
ated but did receive T cells had completely uninfiltrated tumors, whereas the group 
that additionally received irradiation had infiltrated tumors although the amount of T 
cells (22 cells per area) was considerably lower than the baseline infiltration of trans-
ferred TCRtg CD8 positive cells in the RT5 model (165 cells per area, figure 7).  
The independency of stimulation of lymphatic organs by irradiation makes it possible 
to further analyze the mechanism behind the direct activation activation of the tumor 
stroma by irradiation and to characterize the involved cell types. 
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Figure 9. Tumor infiltration by transferred TCRtg T cells in splenectomized RT5 mice 
(A) and allo-transplanted NOD-Scid mice (B). A) RT5 mice (n=7) were splenec-
tomized one week before treatment, left untreated or treated with a local tumor irra-
diation dose of 2 Gy and received after 10 days i.p. injections of TCRtg CD4 positive 
T cells. B) NOD-Scid mice (n=5) received tumor fragments from RT5 mice by subcu-
taneous transplantation, were left untreated or were treated with a local tumor irradia-
tion dose of 2 Gy and received after 10 days i.p. injections of TCRtg CD8 positive T 
cells. A, B) Tumors were excised after one week and analyzed by immunohistochem-
istry for CD3 (white bar), CD4 (blue bar) and CD8 positive (red bar) T cells. 
* P < 0.05; (two-tailed Student's t-test). 
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3.3 Innate immune cells mediate therapy outcome 
3.3.1 Macrophage ablation prevents tumor infiltration by adoptively 
transferred T cells 
The above mentioned results strongly indicate the requirement of low dose irradiation 
of the tumor to allow for the effective infiltration of transferred tumor reactive T cells. 
However, the target population of tumor residing cells that is capable to break the 
tumors resistance to infiltration is not identified. Several studies have shown that low 
dose irradiation can stimulate macrophages (Ibuki and Goto, 1997; Knoops et al., 
2007) and that macrophages have been identified as regulators in the context of lym-
phocytic tumor infiltration (reviewed in Allavena et al., 2008). Therefore, investiga-
tions were undertaken to block macrophage cells or cell functions to interfere with the 
treatment protocol.  
Clodronate loaded liposomes (CLIP) were used to deplete macrophages in vivo. RT5 
mice were treated using LD irradiation with 2 Gy and adoptive T cell transfer of 
TCRtg CD4 or CD8 positive T cells and received CLIP or control liposome injections 
over the time span of the experimental procedure. Liposomes were administered in-
tra-peritoneally and tumor infiltration by T cells as was assessed using immunohisto-
chemistry (figure 10). Tumors from irradiated mice treated with control liposomes 
and TCRtg CD4 positive T cells had strongly infiltrated tumors with a total T cell count 
of 108 CD3 positive T cells 68 CD4 positive T cells and 48 CD8 positive T cells per 
tissue area. Tumors from irradiated mice treated with control liposomes and TCRtg 
CD8 positive T cells had strongly infiltrated tumors with a total T cell count of 480 
CD3 positive T cells and 471 CD8 positive T cells. Administration of clodronate 
loaded liposomes instead of control liposomes together with TCRtg CD4 or CD8 posi-
tive T cells in irradiated RT5 mice reduced the numbers of total infiltrating T cells to 
numbers as low as 15 CD3 positive T cells or 136 CD3 positive T cells per area, re-
spectively. There was no significant difference in respect to T cell tumor infiltration in 
animals that received CLIP and TCRtg CD4 or CD8 positive T cells whether animals 
were irradiated or not.  
The depletion experiments demonstrated that tumor residing macrophages may be 
directly affected by local LD irradiation in vivo, because after macrophage ablation 
massive tumor infiltration by T cells was no longer possible.  
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Figure 10. LD irradiation triggered tumor infiltration by transferred TCRtg T cells is 
abrogated by depletion of macrophages. RT5 mice (n=15) were given repeated injec-
tions of clodronate (CLIP) or saline (PLIP) loaded liposomes i.p. starting one week 
before treatment, were left untreated or treated with a local tumor irradiation dose of 
2 Gy and received after 10 days i.p. injections of TCRtg CD4 (A) or CD8 (B) positive 
T cells, respectively. Tumors were excised after one week and analyzed by immuno-
histochemistry for CD3 (white bar), CD4 (blue bar) and CD8 positive (red bar) T cells. 
* P < 0.05; (two-tailed Student's t-test). 
 
3.3.2 iNOS regulates tumor infiltration by adoptively transferred CD8 
positive T cells 
This study demonstrated, that low dose irradiation can induce tumor derived endo-
thelial cells to upregulate lymphocyte transmigration associated factors in vitro and 
that macrophage depletion abrogates massive T cell tumor infiltration induced by lo-
cal LD irradiation and adoptive T cell transfer in vivo. Yet, there is no evidence for a 
regulation of endothelial cell function by macrophages. One major regulator of the 
endothelial cell layer permeability is macrophage derived nitric oxide (NO) (Fukumura 
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et al., 1997). Blocking of NO synthase therefore may interfere with the macrophages 
ability to control endothelial cell function. Figure 11 shows the impact of the inducible 
nitric oxide synthase (iNOS) inhibiting drug 1400W administered trough slow-release 
micro-osmotic pumps implanted in RT5 mice on T cell tumor infiltration. The drug 
1400W is active in vivo and was released trough the implants over a time span of 2 
weeks. The treatment protocol of LD irradiation with a dose of 2 Gy and adoptive T 
cell transfer of TCRtg CD4 or CD8 positive T cells was used for RT5 mice which re-
ceived 1400W or saline loaded pumps. T cell tumor infiltration by CD3, CD4 or CD8 
positive T cells was not impaired in irradiated mice given CD4 positive T cells and 
1400W according to statistical testing, although absolute numbers were lower than in 
the control group which received saline loaded pumps. However, a clear impairment 
was detected in the CD8 positive T cell transfer system, when 1400W loaded pumps 
were applied before treatment. In this group the infiltration of total CD3 and CD8 posi-
tive T cells was 4 times lower than in the control group which received saline loaded 
pumps (160 vs. 665 CD3 positive T cells per area, 114 vs. 460 CD8 positive T cells 
per area). Implantation of saline loaded pumps did not have a statistically relevant 
effect on T cell tumor infiltration of any subset compared to T cell tumor infiltration 
counts in the control group which did not receive an implant. 
These results show the relevance of NO – which is probably derived from tumor re-
siding macrophages – in regulating massive tumor infiltration by adoptively trans-
ferred CD8 positive T cells into low-dose irradiated RT5 mice. 
 
3.3.3 Macrophage depletion derogates the ability of adoptively trans-
ferred CD4 positive T cells to induce reduction of the tumor mass 
and affects survival 
Tumor reactive T cells that can circulate to the tumor have the ability to induce reduc-
tion of the tumor mass by direct lysis of tumor cells or cytokine mediated effects 
(Shankaran et al., 2001; Street et al., 2001; van den Broek et al., 1996). In the pre-
sent study it was tested whether the use of LD irradiation with 2 Gy and adoptive T 
cell transfer of TCRtg CD4 or CD8 positive T cells in RT5 mice can interfere with tu-
mor growth and how ablation of macrophages using clodronate loaded liposomes 
(CLIP) influences T cell effector functions (figure 12 and figure 14). Tumor growth 
RESULTS 
Page |  61 
was measured indirectly using amperometric capillary blood glucose measurement. 
Reduction of insulin producing tumor cells was indicated by higher than normal levels 
of blood glucose (>80mg/dL) after irradiated animals received the first infusion of 
TCRtg CD4 positive T cells but no clodronate loaded liposomes (38 mg/dL over nor-
mal blood glucose, week 25) or the same treatment and additional injections of saline 
loaded liposomes (31 mg/dL over normal blood glucose, week 26). In all other treat-
ment groups no reduction of tumor cells after the first infusion of T cells were de-
tected as their blood glucose levels were equal to or lower than normal. After the 
second infusion of T cells blood glucose levels failed to be normalized in all groups 
observed. Instead, the same two treatment groups that showed reduction of insulin 
producing tumor cells after the first infusion of TCRtg CD4 positive T cells showed 
stabilized blood glucose levels after the second infusion for up to 2 weeks. The above 
mentioned results were tested using Spearman's rank correlation. Given the mono-
tonic relation of age and blood glucose in this mouse model – since blood glucose 
decreases with age – and a total of 16 XY pairs, a threshold value of r was set at -0.5 
to indicate a significant difference in the course of blood glucose decrease. According 
to this test, only the group that received infusions of TCRtg CD4 positive T cells but 
no clodronate loaded liposomes after irradiation responded to the treatment (r = -
0,359). 
In summary, the reduction in insulin producing tumor cells could be detected only in 
the groups treated with the combination of LD irradiation and T cell transfer without 
injections of CLIP. No such effect was detected when CLIP were added to the combi-
nation treatment, when CLIP and T cell transfers were applied or in the mono-therapy 
conditions. Therefore, the macrophage depletion which abrogated the massive T cell 
infiltration into tumors that received combination treatment of LD irradiation and T cell 
transfer also derogated the ability of T cells to induce reduction of the tumor mass. 
It was investigated, whether the observed transient normalization of blood glucose 
levels and the delayed decrease after the T cell infusions would lead to benefit in 
survival of RT5 mice (figure 13). Statistically significant benefit was assessed by Lo-
grank tests indicating improved survival for the group of animals that received LD 
irradiation with a dose of 2 Gy and adoptive T cell transfer of TCRtg CD4 positive T 
cells but no liposome injections (p=0.0039 vs. untreated group) and for the group that 
received the same treatment and saline loaded liposomes (p=0.0296 vs. untreated 
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group). The median survival of these groups was 6 or 4 weeks longer than that of the 
untreated group, respectively.  
Improved survival could be observed only in the groups treated with the combination 
of LD irradiation and T cell transfer without injections of CLIP. When CLIP were 
added to the combination treatment or when CLIP and T cell transfers were applied 
or in the mono-therapy conditions survival was not improved. These survival experi-
ments reflect the results gained from the monitoring of tumor cell death via meas-
urements of blood glucose, in which only the combination of LD irradiation and T cell 
transfer without injections of CLIP was able to induce reduction in insulin producing 
tumor cells (figure 12), demonstrating the role of tumor infiltrating T cells in tumor 
regression. 
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Figure 11. LD irradiation triggered tumor infiltration by transferred TCRtg T cells is 
abrogated by iNOS blocking. RT5 mice (n=21) received 1400W or saline loaded as a 
subcutaneous implant one day before treatment. Mice were left untreated or treated 
with a local tumor irradiation dose of 2 Gy and received after 10 days i.p. injections of 
TCRtg CD4 (A) or CD8 (B) positive T cells, respectively. Tumors were excised after 
one week and analyzed by immunohistochemistry for CD3 (white bar), CD4 (blue 
bar) and CD8 positive (red bar) t cells. 
* P < 0.05; (two-tailed Student's t-test). 
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Figure 12. Tumor growth after LD irradiation and adoptive transfer of TCRtg CD4 posi-
tive T cells with and without macrophage ablation. Tumor growth was measured indi-
rectly using an amperometric capillary blood glucose reader once weekly in RT5 mice 
treated with a local tumor irradiation dose of 2 Gy and received i.p. injections of TCRtg 
CD4 10 days later (2cd4), in mice with the same treatment plus clodronate (2clipcd4) or 
saline loaded liposomes (2plipcd4), and in mice that received only the irradiation (2), 
only the T cell infusion (cd4), or clodronate (2clipcd4) loaded liposomes and T cells 
(clipdcd4). A depicts the time course of blood glucose of all treatment groups as means, 
B shows each replicate from each group. (A, B) Horizontal dotted line: Normal blood 
glucose level at 80 mg/dL; 1st vertical dotted line: 2Gy irradiation (LD); 2nd and 3rd verti-
cal dotted line: intravenous T cell infusions (TC). 
† r < -0.5; (Spearman's rank correlation test). 
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Figure 13. Survival of RT5 mice after LD irradiation and adoptive transfer of TCRtg CD4 
positive T cells with and without macrophage ablation. RT5 mouse survival is shown for 
animals treated with a local tumor irradiation dose of 2 Gy and received i.p. injections of 
TCRtg CD4 10 days later (2cd4), in mice with the same treatment plus clodronate 
(2clipcd4) or saline loaded liposomes (2plipcd4), and in mice that received only 2 Gy 
irradiation (2), only a CD4 positive T cell infusion (cd4), or clodronate (2clipcd4) loaded 
liposomes and T cells (clipdcd4). 1st vertical dotted line: 2Gy irradiation (LD); 2nd and 3rd 
vertical dotted line: intravenous T cell infusions (TC). 
* P < 0.05; (Mantel-Cox test). 
 
3.3.4 Macrophage depletion can interfere with or enhance treatment 
of RT5 mice using adoptive transfer of CD8 positive T cells  
Since infusions of TCRtg CD8 positive T cells displayed a stronger infiltration of pan-
creatic tumors and a more pronounced treatment response (figure 7, figure 8), their 
effect on tumor growth and survival was investigated. Upon administration of LD irra-
diation and infusion of TCRtg CD8 positive T cells but no liposomes, blood glucose 
levels were higher than normal (40 mg/dL over normal blood glucose, week 27) indi-
cating a reduction in insulin producing cells (figure 14). Addition of saline loaded li-
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posomes to this regimen also resulted in higher than normal (41 mg/dL over normal 
blood glucose, week 25) blood glucose levels as did injections of clodronate loaded 
liposomes in unirradiated animals that received infusion of TCRtg CD8 positive T 
cells (47 mg/dL over normal blood glucose, week 27). All other groups did not show 
signs of reduced numbers of tumor cells after T cell infusion as their blood glucose 
levels were lower than normal. A second infusion of T cells was not applied. The 
three groups that showed reduction of insulin producing tumor cells after the T cell 
infusion showed retardation in glucose decline for up to 2 weeks compared to control. 
The above mentioned results were tested using Spearman's rank correlation. Accord-
ing to this test, the three above mentioned groups responded to the treatment (r < -
0.5). 
Reduction in insulin producing tumor cells was detected not only in the groups 
treated with the combination of LD irradiation and T cell transfer without injections of 
CLIP but also in the group of unirradiated animals treated with injections of clodro-
nate loaded liposomes and TCRtg CD8 positive T cells. No such effect was detected 
when CLIP were added to the combination treatment or in the mono-therapy condi-
tions. Therefore, the outcome of macrophage depletion which abrogated the massive 
T cell infiltration into tumors that received combination treatment of LD irradiation and 
T cell transfer can interfere with treatment or serve by itself as a stimulatory condition 
that leads to tumor cell death despite of inducing a weak T cell infiltration. 
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Figure 14. Tumor growth after LD irradiation and adoptive transfer of TCRtg CD8 posi-
tive T cells with and without macrophage ablation. Tumor growth was measured indi-
rectly using an amperometric capillary blood glucose reader once weekly in RT5 mice 
treated with a local tumor irradiation dose of 2 Gy and received i.p. injections of TCRtg 
CD8 10 days later (2cd8), in mice with the same treatment plus clodronate (2clipcd8) or 
saline loaded liposomes (2plipcd8), and in mice that received only the irradiation (2), 
only the T cell infusion (cd8), or clodronate (2clipcd8) loaded liposomes and T cells 
(clipcd8). A depicts the time course of blood glucose of all treatment groups as means, 
B shows each replicate from each group. (A, B) Horizontal dotted line: Normal blood 
glucose level at 80 mg/dL; 1st vertical dotted line: 2Gy irradiation (LD); 2nd vertical dotted 
line: intravenous T cell infusion (TC). 
† r < -0.5; (Spearman's rank correlation test). 
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The effect of transient normalization of blood glucose levels and delayed decrease 
after infusions of TCRtg CD8 positive T cells was investigated in terms of benefit in 
survival of RT5 mice (figure 15). Although blood glucose levels measurements indi-
cated a treatment response for the group of animals that received LD irradiation with 
a dose of 2 Gy and adoptive T cell transfer of TCRtg CD8 positive T cells but no lipo-
some injections, Logrank tests indicated no benefit in survival. Likewise, there was no 
survival advantage for the group that received the same treatment and saline loaded 
liposomes, but mice treated with clodronate loaded liposomes and T cells lived sig-
nificantly longer compared to the untreated group (p=0.0212). All other groups 
showed no advantage in survival compared to the untreated group. The median sur-
vival of the group treated with clodronate loaded liposomes and T cells was 3 weeks 
longer than that of the untreated group and only one week for the group of animals 
that received LD irradiation with 2 Gy and adoptive T cell transfer. 
Improved survival was only observed upon treatment with clodronate loaded lipo-
somes and T cells. These results do not reflect the results gained from the monitoring 
of tumor cell death via measurements of blood glucose, in which the combination of 
LD irradiation and T cell transfer without injections of CLIP was able to induce reduc-
tion in insulin producing tumor cells (Figure 14).  
 
3.4 Vaccination with SV40 Tag peptides induces strong T cell 
tumor infiltrates  
Finally, a peptide based homologous prime-boost vaccination protocol was estab-
lished to substitute for the infusion of T cells from congenic donors (figure 16). In 
short, MHC class I and class II restricted peptides from the SV40 Tag protein were 
emulsified and injected under the neck skin of RT5 mice once before and once after 
treatment with 2 Gy irradiation. A significant increase in total CD3 positive tumor infil-
trating T cells was detected upon administration of a single peptide priming injection 
of MHC class II restricted peptides in animals irradiated with a dose of 6 Gy (8 vs. 50 
cells per area; p=0.05) or both priming and boost injections (8 vs. 62 cells per area; 
p=0.004). Irradiation using a dose of 2 Gy was not sufficient to allow for infiltration of 
increased numbers of CD3 positive T cells, both in the prime and in the prime-boost 
setting using MHC class II restricted peptides. In all tumors analyzed, the numbers of 
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infiltrated CD4 positive T cells was low, compared to the effect of adoptively trans-
ferred activated CD4 positive T cells (figure 7A). However, a single vaccination of 
RT5 mice using MHC class I restricted peptides in combination with local tumor irra-
diation with a dose of 6 Gy resulted in significantly higher numbers of CD3 (100 vs. 8 
cells per area, p=0.016), CD4 (20 vs. 3 cells per area, p=0.008), and CD8 positive T 
cells (98 vs. 3 cells per area, p=0.018) compared to control. A second boosting vac-
cination also resulted in higher numbers of CD3 (195 vs. 8 cells per area, p=0.023), 
CD4 (31 vs. 3 cells per area, p=0.017), and CD8 positive T cells (191 vs. 3 cells per 
area, p=0.021) compared to control. However, combination of prime-boost vaccina-
tion and local tumor irradiation with 2 Gy resulted in significantly higher numbers of 
infiltrated CD3 positive T cells (161 vs. 40 cells per area, p=0.043). Priming vaccina-
tion alone did not alter the levels of infiltrating T cells. 
Tumors with strong T cell infiltrates could be recovered from RT5 mice using this ho-
mologous prime-boost vaccination protocol, however, the use of adoptively trans-
ferred T cells resulted in tumors which were infiltrated 3 to 5 times more with T cells 
(figure 7). Moreover, the use of MHC class II restricted peptides failed to induce tu-
mor infiltrating CD4 positive T cells. 
RESULTS 
Page |  70 
20 25 30 35 40
0
50
100
150
2clipcd8
2plipcd8
2
2cd8
clipcd8
untreated
Age [weeks]
P
e
rc
e
n
t 
s
u
rv
iv
a
l
*
LD TC
P
e
rc
e
n
t 
s
u
rv
iv
a
l
 
Figure 15. Survival of RT5 mice after LD irradiation and adoptive transfer of TCRtg 
CD8 positive T cells with and without macrophage ablation. RT5 mouse survival is 
shown for animals treated with a local tumor irradiation dose of 2 Gy and received i.p. 
injections of TCRtg CD8 10 days later (2cd8), in mice with the same treatment plus 
clodronate (2clipcd8) or saline loaded liposomes (2plipcd8), and in mice that received 
only 2 Gy irradiation (2), only a CD8 positive T cell infusion (cd8), or clodronate 
(2clipcd8) loaded liposomes and T cells (clipdcd8). 1st vertical dotted line: 2Gy irra-
diation (LD); 2nd vertical dotted line: intravenous T cell infusion (TC). 
* P < 0.05; (Mantel-Cox test). 
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Figure 16. LD irradiation triggered tumor infiltration by peptide based homologous 
prime-boost vaccination. MHC class I (B) and class II (A) restricted peptides from the 
SV40 Tag protein were emulsified and injected under the neck skin of RT5 mice (A, 
n=13; B, n=17) in some groups. Mice were treated with a local tumor irradiation dose 
of 2 Gy or 6 Gy and received either no vaccination, vaccination one week before irra-
diation or both one week before and one week after irradiation. Tumors were excised 
after one week and analyzed by immunohistochemistry for CD3 (white bar), CD4 
(blue bar) and CD8 positive (red bar) t cells. 
* P < 0.05; (two-tailed Student's t-test). 
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4 Discussion 
An effective T cell response against tumors requires an activated tumor stroma 
(Ganss et al., 2002; Garbi et al., 2004). As various studies have shown, the tumor 
stroma is crucially important in the setting of immunotherapy, as it influences the local 
priming of T cells (Spiotto et al., 2002), access of lymphocytes into tumor tissue 
(Ganss et al., 2002; Garbi et al., 2004) and acts as direct target for immune destruc-
tion (Qin and Blankenstein, 2000; Qin et al., 2003). Blood vessels, as a major com-
ponent of the tumor stroma, have long been recognized as targets for cancer thera-
pies (Folkman, 1972). Although endothelial cells regulate the influx of lymphoid cells 
into tissues, it is unclear which factors dictate the state of both activation and anergy 
of endothelial cells in tumors. This work demonstrates for the first time a correlation 
between local LD irradiation induced NO release from activated tumor stroma cells, 
most likely macrophages, and infiltration of tumor-specific effector T cells which was 
probably governed by functional changes in the tumor endothelium.  
 
4.1 In vitro response to LD radiation 
4.1.1 Intermediate irradiation doses of 1 to 2 Gy induce activation of 
tumor endothelium in vitro 
It was reported that irradiation induced tumor infiltration relies on the generation of an 
inflammatory tumor environment allowing adoptively transferred T cells to transmi-
grate into the tumor (Ganss et al., 2002). This inflammatory tumor environment is 
characterized by endothelial cells, which have been activated by inflammatory cyto-
kines to express adhesion molecules and synthesize chemokines and lipid chemoat-
tractants that are presented their luminal surface (reviewed in Ley et al., 2007). To 
elucidate the role of radiation induced endothelial activation manifested in enhanced 
expression of endothelial adhesion molecules, direct irradiation of pancreatic tumor 
derived HPMEC was performed. Treatment of in vitro cultured HPMEC with LD irra-
diation induced an activated phenotype in HPMEC as confirmed by flow cytometric 
measurement of the expression of extra-cellular endothelial molecules (figure 2). 
This activation was manifested in terms of enhanced expression of the cell surface 
molecules P-selectin, ICAM1, ICAM2, MAdCAM1, VCAM1 and ALCAM. Interestingly, 
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irradiation using the highest dose (6Gy) induced the strongest upregulation in all of 
the tested molecules, whereas the intermediate doses (1 or 2 Gy, respectively) re-
sulted in an intermediate activation in most of those factors.  
The above mentioned results are in accord with findings in the field of treatment of 
chronic inflammatory malignancies using low dose irradiation, which demonstrate 
that irradiation doses of 1 Gy or lower have immunosuppressive properties and in-
duce endothelial anergy, characterized by low expression of endothelial cell adhesion 
molecules and low lymphocytic binding strength (Hildebrandt et al., 2002; Kern et al., 
2000; Roedel et al., 2002). Those studies also highlight that irradiation doses of 1 to 
2 Gy can activate endothelial cells which in turn is characterized by upregulation of 
endothelial cell adhesion molecules. However, tumor derived endothelial cells are 
already in a state of reduced expression of leukocyte adhesion receptors and unre-
sponsiveness to inflammatory stimuli (Griffioen et al., 1996; Nooijen et al., 1998; Wu 
et al., 1992). In the present study, the intermediate irradiation doses of 1 to 2 Gy were 
able to convert tumor endothelial cells back to a normal activation state and higher 
doses further activated it. This indicated that intermediate irradiation doses are al-
ready able to restore transmigration relevant functions in tumor endothelial cells, but 
higher irradiation doses may induce a highly activated endothelium reminiscent of 
that in inflammatory conditions. A highly activated endothelium may be able to greatly 
enhance influx of immune effector cells into tumor tissue (reviewed in Danese et al., 
2007). However, in vivo application of irradiation doses of 6 Gy or higher usually re-
sult in severely reduced numbers of lymphocytes because of radiation toxicity 
(Ozsahin et al., 2005; Trowell, 1952) and thus may deplete tumor-specific T cells. 
Therefore, activation of tumor endothelium using intermediate irradiation doses of 1 
to 2 Gy would be more suited in a setting of immunotherapy using T cells, since it 
was shown to convert tumor endothelial cells from anergy back to a normal activation 
state without causing substantial toxic effects. 
Although, the results from this in vitro model imply that LD irradiation could be used 
to enhance infiltration of immune cells into tumors, the relevance of endothelial cell 
anergy has so far not been explored in detail for human tumors. In a study of breast 
cancer in patients with ductal carcinoma and in patients with medullary carcinoma, 
the latter group was characterized by tumors with increased amounts of infiltrated 
leukocytes in the tumor, when compared to tumors of patients with ductal carcinomas 
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(Bouma-ter Steege et al., 2004). Intriguingly, higher amounts of angiogenic factors 
were detected in ductal carcinomas, most evident in the expression levels of VEGF, 
which has been shown to synergize with other angiogenic growth factors such as 
FGF, to downregulate ICAM1 thereby inducing endothelial anergy. In another study, 
analysis of tumor tissues of patients with colorectal carcinoma showed a negative 
correlation between expression of VEGF or the number of proliferating endothelial 
cells and leukocyte infiltration (Baeten et al., 2006). Therefore, LD irradiation which 
has been shown to activate endothelium in the present study may hold potential to 
normalize tumor vasculature and thereby induce leukocyte infiltration for the treat-
ment of human tumors. 
 
4.2 Combination treatment using LD radiation and immuno-
therapy 
The use of combined treatment regimens has been used to enhance cancer therapy 
in different experimental setups. In one study, the reagent group cytosine-
phosphorothioate-guanine-containing oligodeoxynucleotides (CpG-ODN) was used. 
CpG-ODN is primarily known to enhance vaccination strategies by promoting DC 
maturation (Brunner et al., 2000) or by blocking regulatory T cells (Yang et al., 2004), 
but it has also been shown to render RT5 tumors permissive for infiltration by pre-
activated effector T cells (Garbi et al., 2004). It was demonstrated that CpG-ODN 
supported the induction phase of an immune response (Kawarada et al., 2001), and 
was taken up by tumor-resident macrophages which in turn triggered up-regulation of 
adhesion molecules on endothelial cells. Similarly, there is evidence that other effi-
cient therapeutic agents such as cyclophosphamide not only enhance the efficacy of 
adoptive transfers (Dudley et al., 2002) but also act on tumor-resident cells (Hanahan 
et al., 2000; Ibe et al., 2001). Therefore, the combination of treatments which target 
the tumor as well as the tumor microenvironment holds potential for future immuno-
therapy protocols. 
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4.2.1 Infiltrating T cells are required for sufficient activation of tumor 
vasculature in vivo 
In the present study, LD irradiation was used to enhance immunotherapy. Irradiation 
was chosen to improve an established adoptive transfer protocol, since it has been 
demonstrated to promote tumor immunity by enabling transferred effector cells to 
proliferate and to persist in vivo (Dummer et al., 2002; North, 1986). Moreover, irra-
diation has been shown to have profound effects on the anergy of tumor endothelium 
and, hence, effector cell extravasation (Ganss et al., 2002).  
In order to test several irradiation doses for their effectiveness in an immunothera-
peutic treatment situation in vivo, LD irradiation of whole tumors was carried out by 
abdominal radiation treatment of RT5 mice. Afterwards, tumors were excised and 
analyzed by immunohistochemistry for the expression of the endothelial marker 
CD31 and the transmigration associated factors P-selectin, E-selectin, ALCAM, 
VCAM1, ICAM1 and MAdCAM1.  
Local LD irradiation did not cause irreversible damage to microvascular cells as sup-
ported by the observed full revascularization after therapy. Moreover, local LD irradia-
tion influenced the morphology of endothelial cells in terms of elongation and induced 
enhanced intercellular binding strength as indicated by an increased expression of 
the molecule CD31 when the highest dose (6 Gy) was applied (figure 4). These ob-
servations indicated that endothelial cells reverted from an angiogenic to a resting 
phase, a process which is usually accompanied by dilatation of surviving vessels 
(Dimitrievich et al., 1984). Interestingly, no expression of transmigration associated 
factors was found on endothelial cells after radiation therapy. In a report about tumor 
treatment using radiation therapy and T cell transfer, significant expression of ICAM 
and VCAM was observed only when both regimens were combined, but not when 
radiation alone was used (Quezada et al., 2008). This suggests that infiltrating T cells 
are, at least in part, an important factor in further increasing vasculature activation. 
Moreover, corroborating evidence for this hypothesis can be gained from a study of 
tumor-specific T cells in a murine tumor model showing that combined TNF-α and 
IFN-γ signalling induced secretion of antiangiogenic chemokines and prevented tu-
mor angiogenesis (Müller-Hermelink et al., 2008). Therefore, in the present study a 
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therapeutic approach using a combination of local LD irradiation and adoptive trans-
fers of tumor-specific T cells for the treatment of tumor-bearing mice was employed. 
 
4.2.2 Local LD irradiation and adoptive transfer of activated tumor-
specific CD4 or CD8 positive T cells induces massive tumor infil-
tration of both T cell subsets 
Immunotherapeutic treatment of cancer is frequently hindered by insufficient infiltra-
tion as a result of the tumors intrinsic resistance to t cell infiltration and effector func-
tion. However, this barrier can be overcome by inducing an activated tumor microen-
vironment utilizing whole body irradiation in mice. In a report from Ganss and 
colleagues a combination of whole body irradiation and adoptive transfers of tumor-
specific T cells triggered an inflammatory response at the tumor site (Ganss et al., 
2002). This treatment regimen resulted in complete regression of established, highly 
vascularized tumors over a period of weeks.  
In the present study, the same transgenic mouse model was employed. Following in 
vitro activation, tumor-specific TCRtg T cells derived from donor mice were injected 
into RT5 mice previously irradiated with doses ranging from 0.5Gy to 6Gy. Immuno-
histochemical assessment revealed that tumors from mice treated with local LD irra-
diation and adoptive transfer of activated tumor-specific CD4 or CD8 positive T cells 
induced massive tumor infiltration of both T cell subsets (figure 7). T cells transferred 
into animals without previous local LD irradiation caused only mild tumor T cell infil-
tration, comparable to the extent of spontaneous T cell infiltration observed when tu-
mors were treated using irradiation only (figure 5).  
In the CD4 positive T cell transfer setup, all irradiation doses except the dose of 0.5 
Gy resulted in massive tumor infiltration of both CD3 and CD4 positive T cells. As 
seen in the vitro experiments of this study, LD irradiation of 0.5 Gy was also not suffi-
cient to activate HPMEC. The significance of this finding is bolstered by observations 
in the field of treatment of chronic inflammatory malignancies using low dose irradia-
tion, which demonstrated that LD irradiation of 0.5 Gy induced endothelial anergy 
also in their models (Hildebrandt et al., 2002; Kern et al., 2000; Roedel et al., 2002). 
The dependency of T cell tumor infiltration on the activation of the endothelium be-
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comes more evident, when the increase of CD4 positive T cell infiltration along with 
higher irradiation doses and the observation of the highest CD4 positive T cell infiltra-
tion with the highest irradiation dose (6 Gy) are taken into consideration. This ten-
dency was also detectable in the vitro experiments of this study, in which 6 Gy was 
the most potent activator of HPMEC. Therefore, it can be assumed that tumor infiltra-
tion of CD4 positive T cells is dependent on the activation status of the endothelium. 
However, when CD8 positive T cells were transferred into irradiated hosts, an irradia-
tion dose of 0.5 Gy was sufficient to induce massive T cell infiltration, indicating a dif-
ference in the homing capacities of T cell subsets. There is only sparse information 
available about differential homing of CD4 positive and CD8 positive T cells to tis-
sues. One study highlights that a substantial proportion of CD4 positive effector T 
cells migrates to the small intestine in a CCR9-independent fashion, whereas CD8 
positive effector T cells do not (Stenstad et al., 2006). Likewise, it would be possible 
that tumor infiltration of CD4 positive T cells is dependent on the activation status of 
the endothelium, because expression patterns of homing receptors on CD4 positive T 
cells may be differentially expressed.  
Along with CD4 positive T cell infiltration, concomitant infiltration of host CD8 positive 
T cells was observed and resulted in absolute numbers of tumor infiltrating T cells 
equal to those of the CD4 positive T cell subset. Concomitant CD8 positive T cell infil-
tration was impaired when the dose of 0.5 Gy was applied, pointing at the role of CD4 
help which was reduced since levels of CD8 positive T cells were also reduced at this 
dose. Application of an irradiation dose of 6 Gy also resulted in lower frequencies of 
concomitantly tumor infiltrating CD8 positive T cells, probably a result irradiation tox-
icity on the host subset. 
Treatment of RT5 animals with local LD irradiation and transfer of CD8 positive T 
cells resulted in a massive tumor infiltration of both CD3 and CD8 positive T cells re-
gardless of the irradiation dose applied. Irradiation with 0.5 Gy induced a marked re-
cruitment of host Treg to the tumor. The same effect of Treg recruitment after irradia-
tion with a dose of 0.5 Gy has been described in the context of treatment of 
autoimmune malignancies such as rheumatoid arthritis and encephalomyelitis. In 
these studies, irradiation induced low-intensity myeloablation mediated Treg activa-
tion and increment in the proportion of Tregs despite the overall reduction in lympho-
cyte counts (Tsukimoto et al., 2008; Weng et al., 2010). Additionally, it was shown 
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that Treg can dampen tumor-specific immune responses (Ghiringhelli et al., 2004; 
Steitz et al., 2001) and accumulate in tumor beds and tumor draining lymph nodes, 
leading to tumor progression (Ghiringhelli et al., 2005). Therefore, although effec-
tively recruiting CD3 and CD8 positive T cells to the tumor, the treatment regimen 
using 0.5 Gy would not be an adequate solution for the therapy of cancer where a 
sustained T cell effector response would be beneficial.  
Surprisingly, in the present study the irradiation dose of 0.5 Gy was not only sufficient 
to induce infiltration of both CD3 and CD8 positive T cells, but induced the highest 
concomitant infiltration of CD4 positive T cells. Higher doses of irradiation impaired 
the effectiveness of recruitment of host CD4 positive T cells to the tumor.  
 
4.2.3 Combination treatment efficacy relies on CD8 positive T cells for 
vascular normalization of the tumor endothelium 
As mentioned above, the report from Ganss and colleagues described a combination 
of whole body irradiation and repetitive adoptive transfers of tumor-specific T cells as 
responsible for the induction of an inflammatory response at the tumor site (Ganss et 
al., 2002). In their study, irradiation was used to render solid tumors accessible for 
effector cell infiltration, which coincided with conversion of the heterogeneous, tortu-
ous tumor vasculature into a homogeneous network of capillaries as found in normal 
tissue, a process which was called vascular normalization. As a result, complete re-
gression of established, highly vascularized tumors over a period of weeks was 
achieved. Since normalization of the vasculature was found to be a prerequisite to 
break tumor growth promotion and to optimize access of anticancer immune cells, 
normalization of the tumor vasculature was used as a measure of treatment re-
sponse in the present study 
The treatment response was quantified by means of vascular normalization events in 
all tumors (figure 8). Normalization was induced most effectively by transferred CD8 
positive T cells when the irradiation dose was equal to or higher than 1 Gy. Since 
CD8 positive T cells are generally required for vascular normalization (Hamzah et al., 
2008) it is not surprising that CD4 positive T cells were not as potent at inducing 
normalization in the tumors, because of the relatively low levels of CD8 positive T 
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cells which were recruited to the tumor. As vascular normalization is a prerequisite for 
immune destruction (Hamzah et al., 2008), the weak treatment response using CD4 
positive T cells indicates that repetitive administrations of CD4 positive T cells would 
be required to interfere with tumor growth.  
The idea of vascular normalization of the tumor endothelium as a prerequisite for tu-
mor destruction has received much attention in the past years. Several studies are 
indicating that immunotherapy does at least not fully rely on the direct killing of tumor 
cells. In an mouse model using IFN-γ- and IFN-γ receptor-knockout variants, rejec-
tion of transplanted tumors by CD4 positive or CD8 positive T cells was not mediated 
by direct tumor cell killing, but by secretion of IFN-γ which in turn inhibited angio-
genesis (Qin and Blankenstein, 2000; Qin et al., 2003). Other studies have shown 
that cytokine mediated tumor rejection targeted tumor-resident fibroblasts that indi-
rectly interfered with angiogenesis (Schuler et al., 1999) and that cytokines were 
critical in the prevention of spontaneous carcinogenesis by reducing angiogenic ac-
tivities (Nanni et al., 2001). Finally, the concept of vascular normalization using im-
munotherapy was demonstrated in RT5 mice where inflammation in the right context 
led to vessel normalization (Ganss et al., 2002), demonstrating that angiogenesis is 
reversible and that vascular cells can change the dynamics from a tumor-favoring to 
a tumor-antagonistic environment during immunotherapy. 
However, the complex cascade of events that leads to reduced angiogenesis and 
permits effector T cell entry into tumors is still not understood. Elucidating the mecha-
nisms will allow a specific targeting of the tumor environment and further improve 
therapeutic efficacies by providing proinflammatory factors locally rather than sys-
temically.  
 
4.2.4 Massive T cell tumor infiltration can be achieved by a focused ir-
radiation of the tumor mass 
Systemic immunomodulatory effects can be induced by local irradiation of lymphoid 
tissues which is manifested mainly in terms of production of pro-inflammatory cyto-
kines and other inducers of DC maturation (Hallahan et al., 1989; Ishihara et al., 
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1993). To exclude enhanced T cell activation induced in irradiated spleen or lymph 
nodes, two different experimental approaches were used (figure 9).  
In the first approach, TCRtg T cells were transferred into locally irradiated splenec-
tomized RT5 mice to prevent that the transferred T cells get further activated and that 
host T cells get activated by irradiation induced mature splenic dendritic cells. Highly 
infiltrated tumors were recovered from these mice indicating that irradiation of the 
spleen was not required. 
In the second approach, TCRtg T cells were transferred into NOD/Scid mice that 
have received an allo-transplanted RT5 tumor sub-cutaneously. Irradiation of solely 
the tumor which was located beneath the skin, but not of abdominal organs or lymph 
nodes was achieved in this setup. Although the amount of recovered T cells from the 
subcutaneous tumors were much lower, there was a striking difference between the 
irradiated and unirradiated groups that were treated with adoptive T cell transfers, 
suggesting the crucial role of irradiation of the tumor but not other tissues for T cell 
tumor infiltration. Considering that massive tumor T cell infiltration can be achieved 
by a focused irradiation of the tumor mass, the local LD irradiation regimen in combi-
nation with transfer of TCRtg T cells should be widely applicable and complications 
involving damage of organs could be minimized. 
 
4.3 Innate immune cells mediate therapy outcome 
4.3.1 Depletion of macrophages abrogates LD irradiation triggered 
tumor infiltration by transferred TCRtg T cells 
Two reports that used the RT5 mouse model demonstrated that inflammatory stimuli 
like whole body irradiation (Ganss et al., 2002) or systemic application of adjuvants 
(Garbi et al., 2004) were sufficient to allow dramatic infiltration of tumor-specific T 
cells into pancreatic tumors and were linked to activation of tissue-resident macro-
phages which probably induced a strong up-regulation of adhesion molecules on 
blood vessel endothelia. Moreover, several studies have shown that LD irradiation is 
able to stimulate macrophages (Ibuki and Goto, 1997; Knoops et al., 2007). Given 
the pivotal role of macrophages in the context of lymphocytic tumor infiltration 
(reviewed in Allavena et al., 2008) and their proneness to be activated by irradiation, 
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depletion experiments were carried out using the bisphosphonate clodronate. 
Bisphosphonates are compounds used in the clinic to prevent or inhibit development 
of bone metastases and for the therapy of inflammatory diseases such as rheumatoid 
arthritis and osteoarthritis (Rogers et al., 2000; Ross et al., 2004). The use of 
bisphosphonates as antiangiogenic agents has been found to suppress solid tumour 
growth and metastases (Giraudo et al., 2004). With the encapsulation of clodronate 
into liposomes, an efficient reagent for the selective depletion of macrophages has 
been developed and successfully applied in several immunological studies (Seiler et 
al., 1997; Tyner et al., 2005). In the present study, clodronate loaded liposomes 
(CLIP) were used to deplete macrophages in vivo. Liposomes are multi-lamellar 
nano-particles taken up by phagocytic cells of the reticuloendothelial system. Follow-
ing intra-peritoneal injection of CLIP, apoptosis is induced in phagocytic cells in the 
peritoneum resulting in depletion of these cells. Liposomes can not pass trough 
membranes but reach the blood stream from the peritoneum via the parathymic 
lymph node. CLIP were shown to efficiently deplete macrophages but to some extend 
also monocytes in the blood stream and myeloid DC in the spleen (Gregoriadis, 
2006).  
Using this approach, LD irradiation triggered tumor infiltration by transferred TCRtg T 
cells was abrogated by depletion of macrophages (figure 10). Using immunohisto-
chemical methods, it was assessed whether tumor residing macrophages were de-
pleted (not shown). Although, CLIP were used to deplete macrophages systemically 
no difference in macrophage frequencies could be detected, raising the question, 
whether the tumor-resident macrophage population was depleted. CLIP have been 
shown to reach tumor vessels (Zeisberger et al., 2006), but usually cannot pass 
through endothelial cells. Since CLIP were injected into the peritoneum in this study, 
they must have depleted peritoneal macrophages first. CLIP can then leave the peri-
toneal cavity via lymph nodes and reach the blood stream where they deplete mono-
cytes (Gregoriadis, 2006). Circulating to various organs, CLIP can deplete other sub-
sets of the reticuloendothelial system such as macrophages in the liver, spleen and 
bone marrow (Gregoriadis, 2006). Given that CLIP therapy will thereby deplete most 
subsets of the reticuloendothelial system and phagocytic cells in the peritoneum and 
blood stream, it is likely that the effect of macrophage depletion on LD irradiation trig-
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gered tumor infiltration can be attributed to systemic effects of macrophage depletion 
rather than local effects of macrophage depletion in the tumor.  
Regardless of whether systemic or local effects may have interfered with the therapy 
outcome, this study clearly highlights the role of macrophages in mediating tumor 
permissiveness to T cell infiltration. It may be assumed that LD irradiation activated 
macrophages which probably induced an up-regulation of adhesion molecules on 
tumor microvessels and that macrophage depletion interferes with this process. 
 
4.3.2 Tumor infiltration by CD8 positive T cells highly depends on 
iNOS activity 
It was reported that vascular normalization coincides with massive lymphocytic tumor 
infiltration after irradiation treatment (Ganss et al., 2002) and that gamma irradiation 
can induce enhanced NO generation from macrophages (Ibuki and Goto, 1997) 
which is known to be one major regulator of the endothelial cell layer permeability 
(Fukumura et al., 1997). Therefore, it was tested whether blocking of inducible nitric 
oxide synthase (iNOS) may interfere with the macrophages ability to control endothe-
lial cell function. The iNOS inhibiting drug 1400W (N- [[3- (Aminomethyl) phenyl] 
methyl] -ethanimidamide) was administered continuously by sub-cutaneously im-
planted slow-release mini-osmotic pumps. The drug 1400W is a slow, tight binding, 
potent and highly selective inhibitor of iNOS, which is cell-permeable, active in vivo 
and able to reduce NO levels systemically (Garvey et al., 1997). Release of the drug 
from the pumps was ensured for the whole time of the experimental procedures.  
Levels of CD3 and CD8 positive T cells in the tumors were significantly reduced in 
those animals that received TCRtg CD8 positive T cells and LD irradiation, a weaker 
effect was detected in animals that received TCRtg CD4 positive T cells and LD irra-
diation (figure 11). As reported by others (Forster and Lieberam, 1996; Garbi et al., 
2004), TCRtg tumor-specific CD4 and CD8 positive T cells take different routes when 
infiltrating insulinomas. This finding together with the observed differential depend-
ence on iNOS activity in the present study points to the existence of two different 
mechanisms which are responsible for the infiltration of CD4 and CD8 positive T cells 
into the tumor. The mechanism that controls infiltration of CD4 positive T cells seems 
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to be at least partly independent of NO induced endothelial cell activation of tumor 
vessels, whereas infiltration of CD8 positive T cells depends highly on iNOS activity, 
as highlighted by the iNOS inhibition experiments of the present study.  
The results presented here show for the first time the crucial role of macrophage de-
rived NO for the recruitment of adoptively transferred T cells to the tumor. However, 
depletion of macrophages had a more pronounced effect on tumor infiltration of both 
CD4 and CD8 positive T cells. Therefore, it can be assumed that macrophages con-
trol T cell infiltration not only by NO production.  
 
4.3.3 Combination treatment can result in reduction of tumor cells and 
improved survival, depending on the transferred T cell subset 
Since the present results show that macrophages are heavily involved in the recruit-
ment of T cells to the tumor, experiments have been performed to monitor tumor 
growth as well as survival under the influence of macrophage depleting liposomes. 
When CD4 positive T cells were transferred, normalization of blood glucose levels 
and improved survival was achieved only using the combination of LD irradiation and 
T cell transfer with or without the additional treatment with control liposomes (figure 
12 and figure 13). This result was in line with the immunohistological observation of 
T cell infiltration, which was strongly pronounced only when irradiation and T cell 
transfer were combined and declined when clodronate liposomes where adminis-
tered. Nevertheless, since only two infusions of T cells were given, tumor growth was 
only transiently delayed. Ganss and colleagues reported tumor free mice when 7 in-
fusions were applied (Ganss et al., 2002) and showed that after irradiation and adop-
tive transfer, highly activated tumor-specific lymphocytes were initially found at tumor 
and tumor-draining sites but then disappeared because of activation-induced cell 
death (Webb et al., 1990; Zhang, 1996). Therefore, in the present study the small 
remaining T cell population that infiltrated the tumor after the last T cell infusion was 
given was probably unable to prevent progressive tumor growth and host T cells 
failed to uphold tumor immunity.  
When CD8 positive T cells were transferred, normalization of blood glucose levels 
was achieved not only using the combination of LD irradiation and T cell transfer with 
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or without the additional treatment with control liposomes, but also in the group with 
unirradiated animals that received clodronate liposomes and T cell transfer (figure 
14). Remarkably, the latter group was the only one to show improved survival (figure 
15). This result is not in line with previous observations since the time span of nor-
malized blood glucose levels was 5 weeks which is longer than what was observed in 
the CD4 positive T cell transfer experiments and immunohistological observations of 
T cell infiltration showed much higher numbers of tumor infiltrating T cells than in the 
CD4 positive T cell transfer experiments. Additionally, until week 30 which is the end 
point of normalization of blood glucose levels, about half of the animals had died in 
the treatment groups which had received the combination of LD irradiation and T cell 
transfer with or without the additional treatment with control liposomes. Taken to-
gether, it seems likely that the animals did not die of tumor-induced hypoglycemia but 
of side effects of the therapy. Complications such as sepsis as a result of the insulitis, 
leading to the overproduction of proinflammatory cytokines and causing systemic in-
flammation may have led to animal death. Furthermore, massive lymphoproliferation 
caused by the transferred T cells could lead to fatal multiorgan tissue destruction as 
described in a study that used blocking of the negative T cell regulator CTLA-4 (Tivol 
et al., 1995). 
Normalized blood glucose levels and improved survival were detected in the group 
with unirradiated animals that received clodronate liposomes and T cell transfer. No-
tably, immunohistological examinations proved that treatment with this regimen did 
not result in massive T cell tumor infiltration but in numbers of infiltrating T cells com-
parable to those seen in unirradiated animals that received just the T cell transfer. 
This indicates that massive infiltration of T cells is not a prerequisite for tumor cell 
death and that use of clodronate liposomes may have multiple effects which may in-
crease activation of T cells or may work by a T cell independent effect. Zeisberger 
and colleagues showed that tumor treatment with clodronate encapsulated in lipo-
somes alone resulted in significant inhibition of tumor growth accompanied by a dras-
tic reduction in blood vessel density in the tumor tissue (Zeisberger et al., 2006). This 
effect in combination with the infusion of pre-activated T cells may have favored tu-
mor cell death without massive infiltration of the tumor by T cells which was detected 
in this study.  
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Furthermore, it has been reported that treatment with clodronate encapsulated in li-
posomes not only depletes macrophages in mouse tumor models efficiently 
(Zeisberger et al., 2006), but also results in a significant reduction in peripheral blood 
total MDSCs as well as tumor-associated MDSCs and Gr-1+ MDSCs (Priceman et 
al., 2010). Thus, aforementioned increased activation of T cells which was elicited by 
the use of clodronate liposomes may be triggered by the loss of inhibiting effects from 
MDSC or MDSC-like macrophages in the tumor. Taken together, the treatment of tu-
mors using the combination of clodronate loaded liposomes and T cell transfer may 
be a promising alternative treatment option but still needs more investigation. 
 
4.3.4 Local LD irradiation renders pancreatic tumors permissive to in-
filtration by activated host T cells after peptide vaccination 
The RT5 mice do not express Tag before 6 weeks of age and have preserved the 
ability to efficiently generate effector T cells, if vaccinated before tumor development 
(Garbi et al., 2004; Otahal et al., 2006; Ye et al., 1994). Ganss and colleagues 
showed that these mice could be vaccinated using Tag protein plus CpG oligonucleo-
tides as adjuvant before Tag was expressed in the pancreas resulting in highly infil-
trated tumors (Garbi et al., 2004). At the time point when neoplastic transformation of 
beta-cells had occurred and tumor-induced neo-angiogenesis had started, vaccina-
tion failed in most of the mice. At late stage when solid tumors had formed, vaccina-
tion completely failed. However, throughout the whole time Tag-specific effector T 
cells were induced by vaccination as demonstrated by in vivo kill assays. The combi-
nation of CpG oligonucleotides and infusion of activated Tag-specific lymphocytes 
resulted in progressive insulitis. Thus, it seems that pancreatic tumors are resistant to 
activated host T cells even when a potent proinflammatory stimulus able to support 
an ongoing adoptive immune response is given systemically.  
To assess the capacity of host T cells to infiltrate the tumor tissue after LD irradiation 
treatment, a peptide based homologous prime-boost vaccination protocol was used 
(figure 16). Both vaccination approaches using MHC class I and MHC class II re-
stricted peptides resulted in enhanced numbers of CD3 positive T cells preferentially 
for the 6 Gy irradiation setting, probably as a consequence of higher activation of en-
dothelial cells, as described for in vitro irradiated HPMEC in this study. However, the 
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absolute numbers where lower than in the corresponding group of the adoptive T cell 
therapy groups reflecting the considerable lower numbers of specific T cells in the 
non-transgenic host compartment.  
Surprisingly, vaccination with MHC class II restricted peptides had no impact on the 
numbers of CD4 positive T cells, raising the question about the subset of T cells 
which infiltrated the tumor. It was reported that TCRα/β+ CD4/CD8 double-negative T 
cells have the ability to specifically down-regulate immune responses towards allo-
antigens both in humans and mice (Londei et al., 1989; Zhang et al., 2000). Double-
negative T cells were shown to be found in lymphoid as well as in non-lymphoid tis-
sues and have been shown to take up allo-MHC peptide complexes from antigen-
presenting cells. Since the majority of the tumor infiltrating T cells in the RT5 tumors 
have been identified as CD4/CD8 double-negative, this result points at a putative 
mechanism that leads to the recruitment of this suppressive T cell subset to the tu-
mor, when high tumor antigen amounts are available for MHC class II molecules on 
antigen presenting cells.  
Vaccination of 6 Gy irradiated animals with MHC class I restricted peptides resulted 
in highly infiltrated tumors of both CD4 and CD8 positive T cells and the second 
boosting vaccination showed a clear enhancement in T cell numbers. This demon-
strates the predominant capacity of activated CD8 positive T cells to infiltrate the tu-
mor as it was demonstrated in the context of an adoptive T cell transfer in this study 
and as it has been demonstrated as a spontaneous event (Sato et al., 2005) and af-
ter therapy of human tumors (Yee et al., 2002). Thus, it can be concluded that pan-
creatic tumors are permissive to infiltration by activated host T cells when the tumors 
are treated with local LD irradiation. 
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4.4 Conclusion 
The present study illustrates for the first time the unexpected role of macrophages 
and macrophage derived iNOS activity for the recruitment of T cells to the tumor site. 
Combination treatment of tumor-bearing mice using local low dose irradiation and 
adoptive T cell transfer induced a massive influx of T cells into the tumor. This effect 
correlated with the presence of macrophages in the tumor micromilieu which medi-
ated tumor infiltration of T cells by production of NO. Depletion of this cell population 
or suppression of iNOS prevented the treatment effect.  
The author believes that local LD irradiation treatment holds potential for the devel-
opment of novel anticancer combination therapies, because of its ability to create an 
activated tumor microenvironment to selectively enrich immune effector cells facilitat-
ing immune-mediated tumor destruction without elevated risk of causing adverse ef-
fects. While the enhancing effect of irradiation on adoptive T cell therapy has been 
reported (Ganss et al., 2002), lethal whole body irradiation was required in that study 
and involved bone marrow transplantation, making it excessively elaborate and un-
safe for the use in the clinic. Moreover, this study has proven that the combination of 
local LD irradiation and cellular therapy as means of enhancing both the activity of 
innate immune cells and the frequency of tumor-specific T cells can induce tumor 
immune destruction. While the former was required to make tumors permissive for T 
cell infiltration, the latter ensured regression of tumors. Since there was no evidence 
for complete regression of the malignancy, the requirement of enhanced persistence 
of effector cells has to be addressed in future trials. Furthermore, the study shows 
that activated host T cells are able to infiltrate tumors after peptide vaccination and 
local LD irradiation. Therefore, the use of adjuvants to enhance vaccination efficacy 
in combination with local LD irradiation may further improve current therapy proto-
cols. 
These findings could be translated into an immunotherapeutic treatment of advanced 
carcinomas especially of the gastro-intestinal (GI) tract. While high-dose radiotherapy 
is a powerful anticancer treatment approach, it is associated with severe side effects 
that drastically limit its therapeutic capacity for cancer treatment in the GI tract. Using 
LD irradiation, the outcome of radiotherapy could be substantially improved due to a 
selective reduction of damage to the gastro-intestinal organs. 
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